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Abstract 
Introduction:  
Acute respiratory infections (ARI) are the commonest cause of mortality in 
children <5 years worldwide with viral pathogens being important. The aims of 
MPhil year were threefold:  
1) To describe the epidemiology of viral pathogens in ARI of children <5 
presenting to hospital in Brazil during the emergence of novel H1N1 pandemic  
2) To characterise clinical and epidemiological features of ARI in the novel 
group of rhinoviruses (hRV), hRV-C  
3) To investigate the interaction between interleukin (IL)-17 and IL-13 in RSV 
infection of airway epithelial cells. 
Methods:  
1) Multiplex PCR was utilised to test for viral (including H1N1) and atypical 
bacterial respiratory pathogens in nasopharyngeal aspirates from children <5 
presenting with ARI to IMIP Children’s Hospital in Recife, Brazil.  
2) In samples in which hRV was detected, cDNA was amplified and sequenced 
to compare to traditional and novel hRV strains.  
3) RSV-infected and non-infected bronchial epithelial cell (BEAS-2B) cultures 
were simulated with IL-17, IL-13 and IL-17+IL-13. IL-6 and IL-8 were measured 
by ELISA in culture supernatants.  
Results:  
1) A pathogen was identified in 88% of the 630 children recruited to this study. 
The most commonly detected pathogens were RSV, adenovirus, bocavirus, 
and hRV (33%, 29%, 24% and 19%). Co-detection occurred in 43% of 
samples. Influenza prevalence increased in the second year (3% vs. 15%) 
because of the H1N1 pandemic. Children in whom H1N1 was detected were 
more likely to be admitted to hospital and to be co-infected.  
2) hRV was detected in 19% of ARI. We found no clinical or demographic 
differences between hRV ARI and non-hRV ARI. hRV ARI was more likely to 
present as a co-infection. The majority (84%, n=99) of samples were 
successfully analysed with hRV-A being the most common subtype (71%) and 
all remaining samples being hRV-C (21%). Children in whom hRV-C was 
detected were more likely to present with the diagnosis of episodic viral 
wheeze (EVW) / asthma.  
3) In the presence of IL-17 significantly elevated IL-6 and IL-8 expression was 
observed at 48 hours and 24 hours respectively when BEAS-2Bs were 
infected with RSV. IL-13 caused no increase in IL-6 or IL-8 expression. There 
was no demonstrable synergy between IL-17 and IL-13.  
Discussion:  
We were able to detect a viral or atypical bacterial pathogen in most of our 
cohort. We highlighted the importance of the emerging pathogen H1N1, and 
the prevalence of co-infection. hRV was shown to be an important cause of 
ARI and novel hRV-C was associated with EVW/asthma. IL-17 was shown to 
stimulate inflammatory cytokine production, particularly during RSV infection. 
These findings highlight IL-17 as a potentially important cytokine in airway 
inflammation in RSV disease. 
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1 Introduction 
 
1.1 Definition  
 
The focus of this project is paediatric acute respiratory infection (ARI). 
There are a variety of definitions available for what constitutes ARI although all 
relate to the clinical manifestation of an infection of the airways. The World 
Health Organisation (WHO) defines ARI as a “presumed pneumonia”1, 
concentrating mainly on infection of the lower respiratory tract and producing 
guidelines for clinical diagnosis of pneumonia in absence of radiology.  
Simoes et al describes ARI as infection of the upper and/or lower 
respiratory tract, defining these as: 
 “The upper respiratory tract consists of the airways from the nostrils to 
the vocal cords in the larynx, including the paranasal sinuses and middle ear. 
The lower respiratory tract covers the continuation of the airways from the 
trachea and bronchi to the bronchioles and the alveoli”2. 
 In the literature, ARI is also often defined by clinical parameters. For 
example, Regamey et al defined ARI as “...more than two days with cough or 
wheeze, together with fever >38°C, acute rhinitis, otitis media or pharyngitis”3. 
 For the purpose of this project the definition of ARI will be in keeping 
with that described by Simoes et al with ARI constituting any infection of the 
respiratory tract, both upper and/or lower. We have chosen this definition so 
we can investigate nasopharyngeal responses to infection and determine 
whether they differ in upper and lower respiratory tract infections. 
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1.2 Clinical manifestations of ARI: 
 
 Classification of ARI can be further subdivided based on anatomy and 
clinical manifestation. Thus upper respiratory tract infections are infections 
which occur proximal to the entrance of the airways i.e. from the nostrils and 
mouth to the trachea, and including the paranasal sinuses and the middle ear. 
The lower respiratory tract is any point past the trachea to the terminal end of 
the respiratory tract at the level of the alveoli.2  
In reality many ARIs involve more than one anatomical location, 
especially in the upper respiratory tract. The further classifications and 
diagnoses are described as follows. 
 
1.2.1  Upper Respiratory Tract Infections 
 
 Infection above the level of the trachea is termed an Upper Respiratory 
Tract Infection (URTI). Usually these infections are mild but can progress to 
the lower respiratory tract or cause long term complications. This group can be 
further subdivided by clinical diagnosis which includes rhinitis, sinusitis, ear 
infections, acute pharyngitis/tonsillopharyngitis, epiglottitis and laryngitis/ 
croup2. Often a number of these clinical diagnoses are present at any one 
time.  
 4 
Our study will classify all infections of the upper respiratory tract as an 
“upper respiratory tract infection”, for instance conditions such as coryza, 
earache, sore throat or stridor in the absence of lower respiratory tract 
signs/symptoms. Upper respiratory tract infections/conditions include: 
 Rhinitis: Allergic rhinitis is caused by nasal mucosal inflammation in 
response to an allergen4 5. It affects 60 million people in the USA, 
especially children (estimated cost $11.2billion/year) 6 7 8. Symptoms 
include nasal congestion, post-nasal drip, sneezing, watery eyes, ear 
plugging and frontal headaches7  
 Sinusitis: The mucosal lining of the paranasal sinuses is inflamed in 
87% of URTIs9 10. They often resolve with the respiratory infection but 
can persist as a complication -“acute paranasal sinusitis” 11 12. 
Presentation is similar to rhinitis and usually resolves without treatment 
but represents a large burden on a population - 20 million cases per 
year in the USA11. 
 Ear infection: In infection of the inner ear (“otitis media”) both viral and 
bacterial pathogens are causative 13-15. Treatment is debated, antibiotics 
are often given16. Otitis media is estimated to cost $2.8 billion annually 
in the USA16. 70% of children have experienced at least one episode by 
two years old14. Possible complications are chronic otitis media, hearing 
impairment, mastoiditis, septicaemia, meningitis, formation of abscess 
and mortality13. In developing countries complication rates are higher13. 
 Acute pharyngitis / tonsillopharyngitis: Inflammation of the tonsils and 
pharynx is common, over 50% are of viral origin17. Signs and symptoms 
include fever, painful throat, reddening of the tonsils and pharynx, 
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tonsillar exudates, enlarged and tender cervical lymph nodes, pain 
when swallowing (dysphagia) and headache. Suggestive features of 
bacterial infection form the “Centor criteria” and include tonsillar 
exudates, tender cervical lymphadenopathy, fever and absence of 
cough18 19. Bacterial causes respond well to antibiotics. 
 Epiglottitis: Epiglottitis can acutely obstruct the trachea and is a life 
threatening emergency, 88% of cases are in those <5 years20 21. 
Treatment involves oxygen supplementation, intubation, mechanical 
ventilation and high dose antibiotics21. Estimated mortality is 3.6%, 
however it is now a rare condition in the developed world due to 
vaccination against Haemophilus influenzae b (Hib) 20 22. In October 
1992 (UK) the Hib vaccine was introduced to all children at 2, 3 and 4 
months with uptake of 89-96%23. Annual attack rates in children under 5 
have fallen from 30.9 per 100,000 in 1991/2 to 2 per 100,000 in 1993/4 
in the UK, with 96% reduction in other populations24 25 26.   
 Laryngitis / croup: Spasmodic croup and acute laryngotracheitis are 
caused by viral pathogens especially parainfluenza(PIV) viruses, and 
less commonly influenza, respiratory syncytial virus (RSV), adenovirus 
(AdV) and rhinoviruses(hRVs)27 28. Clinical presentation is inspiratory 
stridor, “barking” cough, hoarseness and breathlessness29. Severe 
signs include abdominal movement on respiration, chest wall in-
drawing, fatigue, hypoxia and respiratory failure29. 85% of cases are 
mild and fewer than 1% present with severe symptoms30. Mortality is 
low, estimated at 1 in 30,000 cases, prognosis is excellent 27 29. 
Treatment has been debated but recently a consensus has been 
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reached; humidified air confers no benefit, mild and moderate patients 
should be given dexamethasone and severe obstruction requires 
adrenaline29.  
 
1.2.2  Lower Respiratory Tract Infections 
 
 Any infection below the level of the trachea is classified as a lower 
respiratory tract infection (LRTI). The main diagnoses are bronchiolitis, 
pneumonia and viral induced wheeze/asthma. In general a LRTI is more 
severe than URTI with increased likelihood of mortality. For this reason much 
of the focus of international agencies is in prevention of lower respiratory 
infections, especially pneumonia. As mentioned previously it is the scope of 
this study to look at both upper and lower respiratory infection. More details on 
the syndromes constituting LRTIs are as follows: 
 
1.2.2.1 Bronchiolitis: 
 
 Bronchiolitis describes “an acute respiratory illness that affects infants 
and young children with coryza and low-grade fever that progresses over a few 
days to cough, tachypnoea, hyperinflation, chest retraction and widespread 
crackles, wheezes or both”31. Bronchiolitis is a common clinical syndrome in 
young infants with hospital admission rates of 30 per 1000 for children younger 
than 1 year31. This condition appears almost exclusively in children less than 1 
year old, with the majority treated with supportive therapy. Mortality rates are 
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currently less that 2 per 100,000 in developed countries (UK)32. The mortality 
due to bronchiolitis has been higher in the past however, in the late 1970s the 
rate in UK was 21 per 100,00032. 
The most common causative pathogen of bronchiolitis is human 
respiratory syncytial virus (RSV). RSV is detected in 42%-75% of children 
presenting with bronchiolitis33-35. Other pathogens have also been detected 
such as AdV, influenza, PiV, hRV, hMPV, coronavirus and human bocavirus33. 
Cases present in a clear seasonal pattern with yearly RSV epidemics in 
temperate climates. In the UK this period is in the winter with presentations of 
bronchiolitis peaking between December and January31. 
Given the clear epidemic peaks and typical clinical signs of bronchiolitis, 
extensive investigations are rarely necessary other than confirmation of RSV 
status by immunofluoresence. Chest radiography demonstrates non-specific 
signs of generalised hyperinflation and patchy atelectasis and can sometimes 
be important in excluding pneumonia31. Clinical signs of a child with 
bronchiolitis include wheeze, tachypnoea, fever, hypoxia, cyanosis and 
crackles on auscultation, with crackles and cyanosis being associated with 
increased severity31. Risk factors for increased severity include prematurity, 
chronic lung disease, congenital heart disease, neuro-disability or 
immunodeficiency31. In some of these high risk groups, use of the monoclonal 
antibody palivizumab has been sanctioned, but it is limited due to excessive 
costs of $5000-$6000 per patient per season31.  
Treatment of bronchiolitis is a subject of ongoing debate within the 
literature. Bronchodilators have been previously used however a Cochrane 
Review showed they have no effect on length of hospitalisation, length of 
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symptom resolution or reduction in hospital admission31. Other treatment 
modalities have also been used with debatable effect such as nebulised 
epinephrine, dexamethasone and heliox. The most effective intervention is 
supportive care with fluid replacement, correction of hypoxia with oxygen and 
other supportive measures, the majority will recover without event31. 
Bronchiolitis is associated with a number of rare complications that are 
important due to severity including encephalopathy and septicaemia31 36. Also 
importantly in bronchiolitis are the long term effects on respiratory physiology 
and its links with recurrent wheeze and asthma in later life. Sigurs et al 
demonstrated that bronchiolitis in infancy was associated with recurrent 
wheeze/asthma at 7 and 13 years of age37 38. However it is still unclear 
whether this relationship is causative or if a child who is predetermined to have 
later asthma may have increased risk of bronchiolitis 39. Current areas of 
ongoing research in bronchiolitis are into the immunological profile of affected 
children. It is hoped that this will characterise the pathology behind this 
common clinical condition40. Other areas of research include the identification 
of clinical, demographic or laboratory detectable risk factors to allow risk 
stratification of patients presenting with bronchiolitis and may reduce the 
number of children progressing to severe disease41. 
Comparatively less is known about bronchiolitis in the developing world. 
A small number of studies have carried out research in Brazil and South 
America which have suggested a seasonal peak in bronchiolitis during the 
rainy season and is supported by studies into RSV prevalence42-44. The 
detection of RSV simultaneously with other respiratory viruses has also been 
shown42. Some studies have also reported bronchiolitis obliterans, an 
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especially severe form of bronchiolitis, to be more prevalent in Brazil45. This 
has highlighted bronchiolitis as an important area of research in South 
America. In South Africa it has also been established that RSV is the main 
causative agent of bronchiolitis but does not have such distinct seasonality as 
Europe and North America, in Cape Town epidemics have been demonstrated 
both in the rainy season and also in the winter46. In Kenya RSV infection was 
identified in 27% of severe paediatric pneumonia47.  
 In this study the diagnosis of bronchiolitis has been defined as a child 
<18months in whom upper respiratory symptoms preceded lower respiratory 
symptoms of wheeze, tachypnoea and signs of respiratory distress. 
 
1.2.2.2 Pneumonia: 
 
 Of all clinical presentations of ARI, pneumonia is most associated with 
mortality. Pneumonia related deaths worldwide in children are estimated to be 
in the region of 1.9 million, not including neonatal mortality48. Many pneumonia 
deaths are in malaria prevalent regions where pneumonia mortality is 
frequently misclassified as malaria48. The WHO reports that pneumonia is the 
predominant cause of ARI mortality49. Pneumonia is highlighted as one of the 
primary targets to reduce worldwide mortality in children under five as part of 
the Millennium Development Goal (MDG)48. Overall incidence of pneumonia 
worldwide is estimated to be 151 million cases per year, of which 7-13% 
require hospital admission50. The majority of pneumonia burden is centred 
around developing countries with 72% of mortality in children from Africa and 
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Asia1. It is estimated half of these deaths could be prevented with vaccination 
and even more could be treated with inexpensive antibiotics, highlighting the 
necessity to confront this condition globally51 
 Clinically URTI often precedes pneumonia. Symptoms of pneumonia 
include fever, rigors, malaise, cough and dyspnoea52. The cough can be 
productive of sputum of a purulent colour. Clinical signs include dyspnoea, 
chest in-drawing, dullness to chest percussion, crackles and/or wheeze on 
auscultation53. Very severe cases may present with convulsions or coma, 
organ failure may be present. In contrast to bronchiolitis, chest radiography is 
important with the WHO producing guidelines on how to diagnose pneumonia 
by radiography54. Signs on radiography include consolidation, infiltrates, 
effusion, atelectasis and peribronchial thickening54. Resource poor countries 
often do not have access to radiography and so the WHO has also defined 
severe pneumonia clinically as the presence of lower chest wall collapse/chest 
in-drawing and treatment requiring hospital admission53.  
 Treatment is with appropriate antibiotics and simple supportive care. 
Initial treatment is with cotrimoxazole or amoxicillin either orally in mild disease 
or intravenously if severe53. Supportive measures are required, these include 
oxygen supplementation, anti-pyretics, adequate nutrition and supplementation 
of feeds52. Simple treatments delivered properly can reduce pneumonia 
mortality in children by 10%, and would only cost a few dollars a child allowing 
widespread use in settings such as Africa or Asia48. Risk factors for more 
severe disease include malnutrition, HIV or other immunosuppressive disease, 
household smoking and cessation of breastfeeding before 6 months of age48.  
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 Vaccination is an effective preventative treatment. Vaccines for the most 
common bacterial agents are already available including H. Influenzae type b 
(Hib) and Streptococcus pneumoniae (pneumococcus). These pathogens are 
discussed in more detail elsewhere, but account for the majority of bacterial 
causes of pneumonia. There are two differing types of vaccination available for 
pneumococcus and Hib – conjugate and polysaccharide. The polysaccharide 
vaccine stimulates an antibody response to specific serotypes of pathogen, 
however a T-cell response is not caused and so vaccine protection is short 
with effectiveness of pneumococcus being reduced from 100% to 8% in 3 
years55. In comparison the more recent conjugate vaccines function by 
coupling the bacterial polysaccharide to a protein carrier, inducing a T and B 
cell response which leads to increased longevity and a “booster” effect when 
re-exposed to the antigen55 
The Hib polysaccharide vaccine reduces the incidence of childhood 
pneumonia by 20% in a developing country and has been available since the 
1980s48. The newer Hib conjugate vaccine is estimated to reduce invasive Hib 
disease by 80%, it is often combined one or more of; hepatitis B, diphtheria-
tetanus-pertussis, and/or inactivated polio vaccines56. The pneumococcal 
conjugate vaccine was developed more recently and there are a number of 
forms. The vaccine for seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 
19F and 23F) accounts for 80% of pneumococcal infections in children and 
was first introduced in 200057. Other vaccines with different serotypes have 
also been developed. Conjugate vaccines are also more effective at 
eliminating carriage of pneumococcus and Hib, increasing the value of 
vaccination on a population scale, a phenomenon termed herd immunity58.  In 
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the USA where vaccination levels are high the 7-valent vaccine reduced infant 
invasive pneumococcal disease by 82%, although a large degree of this is 
generated by herd immunity due to high vaccination uptake57. Interestingly 
nasopharyngeal pneumococcal carriage in children remains constant after 
vaccination with other serotypes being present53 59. Despite this vaccination is 
effective and is prioritised by the world health authorities to achieve the 
MDG60. Another common area of research is characterisation of pathogens 
involved in causation of pneumonia. Previous studies into epidemiology have 
not been able to identify a causative pathogen in all children and new 
methods. This is important to our study looking at causation of ARI, including 
pneumonia. 
 In Brazil and South America pneumonia burden is also significant. In 
Brazil LRTIs, of which the majority are pneumonia, cause 1.4 deaths per 1000 
live births in those <5 years, greater than both diarrhoeal disease (0.8 per 
1000) and accidents or injuries (1.13/1000)45. This has caused pneumonia to 
be one of the main targets in the family health programme (FHP) of Brazil45. 
Much of the FHP is involved in improving protective factors for ARI such as low 
nutrition and breastfeeding, as well as targeting early case diagnosis and 
treatment of pneumonia and other LRTIs61. Similar to other countries, S. 
pneumoniae is a well recognised cause of pneumonia in Brazil, other 
respiratory pathogens, especially viruses, are less researched62.  
 In our study pneumonia will be a clinical diagnosis defined as a child 
with fever, tachypnoea and respiratory distress where focal or diffuse crackles 
or decreased vesicular sounds are present on auscultation. Our classification 
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is based on clinical diagnosis as radiographic investigations are not available 
for all children in our study population. 
 
1.2.2.3 Episodic viral wheeze / Asthma: 
 
 Wheeze is caused by reduction in airway cross section of airway or 
increase in airway compliance63. One third of children in the UK present to a 
healthcare professional with a wheezing episode by 3 years of age64. There is 
clinical overlap between viral induced wheeze of infancy and childhood 
asthma. Wheeze is the predominant clinical sign in both and in the majority of 
cases there is preceding URTI before wheeze appears 1-2 days later. One 
third of the children with episodic viral wheeze as a young child will go on to 
develop atopic asthma64. Overlap is also seen between episodic viral wheeze 
and bronchiolitis, with 75% of children admitted to hospital with acute viral 
bronchiolitis in the first 4 months of life going on to develop subsequent 
episodic wheeze with viral respiratory infection63. Episodic viral wheeze is a 
series of discreet episodes of respiratory distress characterised by wheeze 
whereas asthma later develops into a chronic disease with exacerbations of 
sudden deterioration in airway function, day-to-day variation in airway function 
and fixed or persistent airway obstruction63. 
Risk factors for development of asthma and episodic viral wheeze 
include maternal smoking in pregnancy, history of maternal wheeze, 
prematurity and reduced lung function in the neonatal period63. Treatment is an 
area of debate in which research is ongoing. Bronchodilators and 
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corticosteroids have been the mainstay of asthma treatment for many years. 
These medications have been highlighted for use in episodic viral wheeze with 
Cochrane reviews having been performed on both medications. The review for 
bronchodilators concluded there was no clear benefit in recurrent wheeze for 
children under 2 although some trials included both children who did and did 
not go on to have asthma later in life65. A separate Cochrane review was also 
performed for children under 17 years with episodic viral wheeze and the effect 
of inhaled corticosteroids which concluded high dose corticosteroids were 
effective in the treatment of acute viral induced wheeze and reduced the 
duration of wheeze, however there was no evidence that low dose 
corticosteroids reduce the effect of episodic viral wheeze, a treatment that has 
proven beneficial in children with asthma66. Both of these Cochrane reviews 
advocated further research into episodic viral wheeze treatment.  
The burden of episodic viral wheeze / asthma in young children is 
significant with 26% of children under the age of five receiving inhaled therapy 
for wheezing disorder and a conservative estimate of cost being £91 million 
($145 million) in the UK in 200063. Few population based studies into asthma 
have been undertaken in Brazil, although the Brazilian centres involved in the 
international study of asthma and allergy (ISAAC) reported a prevalence of 5-
22% in children67. One of the few studies focusing on Brazil reported an 
asthma prevalence of 18% in children aged 4 years as well as a EVW 
prevalence at 21%68. This high prevalence is reflected across many countries 
in South America with asthma / EVW representing a significant burden on 
paediatric disease69. 
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Research is ongoing into management of childhood wheeze. Current 
themes in literature investigate the immunology involved of wheeze, the aim 
being to develop targeted treatments or allow detection of children that will go 
on to develop asthma. Work is also ongoing to further stratify infants suffering 
wheeze with hope that early detection will allow more targeted treatment and 
opportunistic prevention and also improve predictions of long term prognosis70.  
All the factors mentioned previously make it difficult to diagnose asthma 
in a child under five with certainty.  Our study will include children under the 
age of five years who will be given the clinical diagnosis “episodic viral wheeze 
(EVW) / asthma” and this will be defined as a child in whom discreet episodes 
of wheeze occurred, often in association with viral URTI.  
 
1.3 Causative pathogens of Acute Respiratory Infections 
 
 There are a variety of respiratory pathogens which can lead to a patient 
suffering from ARI, both viral and bacterial. In some cases no known cause 
can be found in a patient presenting with ARI. Although some causative agents 
have already been alluded to when describing the clinical presentation of ARI 
this section looks to highlight the causative pathogens of ARI. 
 Our study will focus on the viral epidemiology of ARI. A variety of 
bacteria have been implicated in ARI previously. In the past bacteria were 
much more susceptible to culturing techniques allowing research to be 
performed. Viral pathogens are more difficult to detect and culture leading to 
late discovery of pathogens. This is also reflected by developments in 
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preventative treatment of pathogens with vaccines being available for bacterial 
pathogens. Bacterial pathogens that are frequently discovered in childhood 
ARI will be described below but may not be mentioned again in this study due 
to its viral focus.  
 
 
1.3.1 Respiratory Syncytial Virus: 
 
 Human Respiratory Syncytial Virus (RSV) is a member of the 
paramyxovirus family71. The single stranded RNA genome is contained within 
a lipid envelope with surface glycoproteins31. There are two major strains of 
RSV, A and B. Some studies have reported A strain being responsible for 
more severe bronchiolitis71.  RSV is one of the most highly prevalent 
pathogens in childhood respiratory disease and can present as bronchiolitis, 
pneumonia, otitis media, rhinitis or sinusitis72. The most common presentation 
is bronchiolitis, being detected in over 70% of children hospitalised with 
bronchiolitis31 33. RSV is highly seasonal presenting in epidemics, these 
periods are well characterised in the northern hemisphere where they correlate 
with winter71 72. 80% of infants have been infected with RSV by the end of the 
first year of life, and 100% by the end of second31 71. Majority of infections are 
mild but mortality does rarely occur, in 2% of healthy infected children or as 
high as 5% in children with risk factors71. The importance of RSV in 
bronchiolitis has also been highlighted in Brazil with a suggested epidemic in 
the rainy season43. Although this is not as well defined as other countries, 
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Washburne et al observed RSV circulating in Brazilian communities throughout 
the year73. Both subtypes of RSV have been shown to circulate simultaneously 
in Brazil44. 
Risk factors for increased severity include prematurity (associated with 
ten-fold increase in risk), congenital heart disease, immunosupression and 
neurodisability71. Environmental factors  can increase risk of RSV infection 
including passive cigarette smoking, crowded living conditions, older siblings at 
home, early cessation of breastfeeding and low socioeconomic status72. 
Another consideration that increases RSV burden is long term outlook for 
patients who suffer RSV bronchiolitis at a young age. Sly et al has showed that 
if a child has RSV LRTI before 3 years of age then lower lung function and 
airway hyper responsiveness can be demonstrated at 13 years old74. The 
interpretation of these findings is still debated whether RSV causes late 
asthma or whether RSV infection is an early sign of a child’s predisposition to 
asthma31. 
 The immune response to RSV is atypical compared to other respiratory 
viruses. Symptoms begin 3-5 days after inoculation. It is highly contagious 
virus that can be transmitted through direct contact with respiratory secretions 
and indirect inoculation from contaminated surfaces71. Once infected the 
immune system activates T-helper cells that react with expression of cytokines. 
Some research has shown that the immune response to RSV is consistent with 
T helper-2 (Th-2) class of T-helper cell activation such as interleukin-4 (IL-4) 
and interleukin-5 (IL-5) and interlukin-13 (IL-13)31 75. Although a Th-2 response 
is witnessed in other respiratory viruses, such as Adenovirus, the majority of 
other viral infections are normally associated with a T helper-1 (Th-1) response 
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characterised by cytokines such as interferon gamma (IFN-γ)76 31. It is of 
interest that the Th-2 class of cells are also closely associated with patients 
suffering asthma or atopy in later life. However this opinion has been disputed 
by others with some suggesting Th-1 cells and the cytokine IFN-γ plays an 
important role in pathogenesis of RSV bronchiolitis77 78. Further groups have 
suggested that cytokines outside the Th-1/Th-2 classification are important, so 
called “beta cytokines”79 80.  
 A second distinguishing feature of immune response to RSV is the 
ability to re-infect, with the same strain being able to infect the same host time 
after time. This is of interest as the immune memory response to viruses 
usually prevents re-infection. The exact reason for this is unknown, it has been 
hypothesised that RSV inhibits CD8+ T cells and so the immune systems 
memory response is ineffectual81. This explanation is debated however with 
Chang et al suggesting this feature is not specific to RSV and so may not give 
adequate explanation82. 
 An RSV specific humanised monoclonal antibody (palivizumab) was 
developed a decade ago. Its development was a breakthrough in RSV 
prevention and it is effective in reducing episodes of bronchiolitis. The vaccine 
however is costly. Thus palivizumab is only used in children who are at high 
risk of severe RSV disease – those born before 32 weeks gestation, or with 
significant cyanotic heart disease or chronic lung disease31 71.   
 
1.3.2  Adenovirus: 
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Adenoviruses (AdV) are non-enveloped DNA viruses of the family 
Adenoviridae first discovered in 195383. They most commonly present as 
respiratory infections but can cause conjunctivitis and gastroenteritis84. They 
are responsible for 5-10% of respiratory tract infections in children83 85. In 2010 
there were 53 know subtypes of AdV although this is expected to rise85. 
Specific serotypes are associated with different clinical manifestations. 
Common subtypes involved with respiratory infection include HAdv-3, HAdv-7, 
HAdv-1, HAdv-2, HAdv-5 and HAdv-485. The prevalence of different serotypes 
is known to vary geographically and seasonally, with AdVs often appearing as 
endemics especially in overcrowded spaces84.  
AdV infection commonly presents as a LRTI, detected in 73% of cases 
of pneumonia in Korea and 65% in the USA85 86. It is estimated 5% of children 
presenting to hospital with ARI and AdV infection will result in mortality, with 
risk factors including age less than 1 year or presence of co-morbidities85. 
Specific subtypes are associated with severe respiratory infection in children, 
the most common being HAdv-785 87. In contrast to RSV, AdV infections 
present throughout the year with no clear seasonal variation85 88.  
There are few studies into AdV prevalence in South America and Brazil. 
Estimates of prevalence in the South America region have shown AdV to be 
present in 3%-8% of ARI samples89 90. Moura et al also demonstrated AdV to 
predominantly present as LRTI in Brazil, especially pneumonia90. Also AdV 
has shown to be an important pathogen involved in viral gastroenteritis in 
Brazil, presenting in epidemic outbreaks, however it is separate serotypes that 
cause respiratory and GI infection91. 
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The immune response to AdV infection involves airway epithelial cells 
and numerous cytokines and chemokines such as Interleukin 6 (IL-6), Tissue 
Necrosis Factor alpha (TNF-α), Interferon Gamma (IFN-γ) and Interleukin 8 
(IL-8)83. AdV infection is capable of lysing infected airway cells and so can 
directly damage host tissue87. Treatment of AdV is usually supportive the use 
of antivirals is not usually necessary. There is no vaccine widely available, 
although during the 1960s the USA did produce one for military personnel84. 
Cidofovir is an anti-viral drug that has been shown to be effective against AdV 
infection, however due to its side effects which include nephrotoxicity, it is 
used sparingly in disseminated disease or those undergoing stem cell 
transplantation92. 
AdV has been shown to be detected in respiratory samples for a 
significant time after initial infection, in some children the same serotype 
remains for 9 months93. It has also been shown to be present in 0.6-3% of 
children who are asymptomatic93. AdV may remain present in a latent form 
with viral protein remaining in cells and not replicating, this latent infection may 
be capable of amplifying pathology that causes asthma or COPD in later life87.  
This prolonged latent phase has been advantageous in other areas of 
research, with AdV being a popular vector for genetic therapy94.  
 
1.3.3  Rhinovirus: 
 
 Human rhinovirus (hRV) belong to the family of viruses picornaviridae 
along with poliovirus, hepatitis A and enterovirus83. This family of viruses share 
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a non-enveloped structure with single stranded RNA genome (ssRNA)84. First 
discovered in 1950s during research into the cause of the common cold84. Viral 
culturing techniques were used to determine serotypes so by 1987 it was 
discovered there were 101 serotypes of hRV that separated into two – hRV 
group A and hRV group B95. These methods were unreliable and slow, with 
samples often unable to be typed. It was regarded that hRV was a “common 
cold virus” and was limited to the upper respiratory tract meaning little 
significance in causing morbidity. Mild URTIs and the common cold are often 
regarded by physicians as a mild clinical problem but in children accounts for 
22 million days absence from school each year in the USA96. 
 In recent years, research brought a different perspective on hRV 
infection. hRVs can reproduce in and infect the lower respiratory tract and 
cause pneumonia97. hRVs are also the commonest cause asthma 
exacerbations in the young and COPD exacerbation in adults95 98. These 
findings were largely made possible because of the increasing availability of 
RT-PCR, allowing quick and reliable assessment of infective pathogens. These 
findings significantly increase the morbidity of hRV species. hRVs are also one 
of the most common causative pathogens of upper respiratory infections, 
found in up to 90% of URTI, with direct and indirect socio-economic burden in 
both the developed and developing world95 97. In Brazil hRV has been 
highlighted as an especially important pathogen in paediatric patients. De 
Freita Souza et al documented the high prevalence of respiratory viruses of 
children attending day care and suffering ARI in Salvador, hRV was the most 
common virus involved and detected in 21% of samples99.  To date there has 
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been no study in Brazil or South America which describes the role of different 
hRV groups.  
Since the introduction of PCR, many more than the original 101 serotypes 
have been described. Including a recently described group of hRV strains – 
Rhinovirus C, whose role in respiratory infection is has yet to be fully 
described95. This new subgroup of hRV has been shown to be associated with 
severe asthmatic exacerbations compared to traditional groups A and B, being 
detected more frequently in severe paediatric asthma than previous strains100. 
One of the main aims of this study is to described the clinical and demographic 
features of hRV infection and define the role of novel hRV-C in paediatric ARI. 
 
1.3.4  Bocavirus: 
  
 Human bocavirus (hBoV) was described in 2005 by a team in 
Sweden101 102.  It belongs to the family parvovirus and is the first of such 
viruses to be discovered in humans. Despite its recent discovery hBoV 
appears to have an important role in ARI, with antigen studies showing almost 
all children have been exposed by the age of five years101. Exact prevalence of 
hBoV reported in ARI has varied with it being described in 2.9-19% of ARI103. 
 Due to its recent discovery it was initially difficult to fully characterise 
hBoV, requiring developments in ELISA and PCR techniques to fully describe 
its serology. ELISA techniques have been developed to identify hBoV 
antibodies in serum, of both IgG and IgM classes, as well as PCR allowing 
detection in nasal aspirates104. Variation in DNA can further sub-divide hBoV 
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into 4 viral species (hBoV1 – 4) of which hBoV2 appears to be the most 
common105. 
 Clinical presentation of hBoV is similar to other infective agents with 
fever, rhinorrhea, cough and wheeze. hBoV has been detected in both upper 
and LRTIs101. Its exact role is still unclear with few epidemiology studies testing 
for hBoV. Those few studies with a control comparison have demonstrated 
higher prevalence in ARI compared to controls106. Further difficulty has arisen 
with hBoV being frequently detected with other pathogens, co-detections in 50-
60% of cases and in some publications as high as 78%106. Possible roles that 
have been suggested include hBoV having a direct pathogenicity, having low 
pathogenic effect or augmenting the effect of other respiratory pathogens106. 
This lack of knowledge highlights hBoV as an important pathogen for further 
investigation. These limits in knowledge are further demonstrated by the lack 
of epidemiological data on hBoV in Brazil or South America. Albuquerque et al 
showed hBoV to be present in paediatric ARI samples that were further 
analysed after being found negative for other respiratory pathogens107. 
 Transmission of hBoV is currently being studied. There are no 
permissive cell lines or animal models available. It is most likely transmitted by 
aerosol means like other respiratory pathogens, but its detection in 0.8-9.1% of 
childhood gastroenteritis cases suggests it could potentially be transmitted by 
faeco-oral route106. To date there are no specific treatments or vaccines 
available for hBoV. 
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1.3.5  Human Metapneumovirus: 
 
 Human Metapneumovirus (hMPV), discovered relatively recently in 
2001, is of the paramyxovirus family and is the first virus within this family that 
has been shown to infect non-avian hosts101. hMPV is difficult to grow in 
culture making it difficult to analyse its pathogenesis. It was discovered in 
nasopharyngeal aspirates of children with respiratory infection in whom no 
other pathogen could be discovered. It has been reported that hMPV is 
present in between 2% and 20% of ARI and antibodies to HMPV are present in 
100% of children by 5 years of age, which some believe indicate that all 
children are mildly or sub-clinically infected by this pathogen106. 
 Clinically hMPV can present as both URTI and LRTI, although LRTI is 
more common in children under one year of age, being one of the most 
common causes of bronchiolitis second only to RSV106 101. Two distinct genetic 
groups of hMPV have been classified (A and B) each with two separate 
subtypes. Murine models of hMPV have demonstrated that it readily replicates 
in the lower respiratory tract and inflammation peaks 5 days after infection and 
can persist for up to 21 days106. Infection causes activation of both Th-1 and 
Th-2 cytokines although Th-1 cytokines are activated in a lower amount 
compared to RSV infection106. 
 Clinically hMPV has similar presentation to other respiratory viruses with 
wheeze, hypoxia and fever being predominant features101. The majority of 
cases resolve without healthcare presentation or with outpatient care, however 
2% require hospital admission with some progressing to ITU treatment106. No 
specific treatments are currently available. Factors that increase the risk of 
 25 
severe disease are age <1 year, underlying co-morbidities or prematurity106. 
hMPVs interaction with other respiratory pathogens is currently unclear but is 
an area of future interest, as one study has shown co-infection with hMPV and 
RSV increases the risk of a child requiring mechanical ventilation ten-fold 
compared to single infection106. hMPV has been implicated clearly in 
respiratory disease and is only found in 0-1% of asymptomatic children’s 
airways106. Similarly to the recently discovered pathogen hBoV, reports on the 
prevalence of hMPV in Brazil and South America are lacking. Albuquerque et 
al also demonstrated the presence of hMPV in respiratory samples in which no 
other pathogen was detected107. Cuevas et al also showed hMPV to be 
present in 24% of children presenting to hospital with ARI, the only other 
pathogen tested for was RSV42.  
  
1.3.6  Parainfluenza: 
 
 Parainfluenza viruses (PIV) are enveloped single stranded RNA viruses 
of the family Paramyxoviridae108. There are four separate types of PIV 
designated PIV-1, PIV-2, PIV-3 and PIV-4. PIV is detected in between 9% and 
30% of childhood ARI presentations and causes both URTI and LRTI clinical 
manifestations108. There is some variation in clinical presentations between 
PIV types. PIV-1 commonly presents as croup in childhood and can be 
detected in up to 50% of children presenting to hospital with the condition108. 
PIV is also commonly detected in bronchiolitis, although in much smaller 
amounts than RSV, being detected in 10-15% of cases with the most common 
subtypes being PIV-1 and PIV-3108. PIV-1 often presents in epidemics 
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biennially with clinical manifestations of croup or URTI109. These two subtypes 
are similarly the most common PIV subtypes detected in childhood pneumonia 
specimens, where PIV is detected in 10-18% of pneumonias, PIV-1 is usually 
associated with secondary bacterial infection pneumonia108 110. Relatively little 
is known about PIV-4 subtype compared to other groups. 
 Transmission methods of PIV have not been confirmed although it has 
become apparent that it is unlikely to be transmitted by aerosol methods, 
contaminated surfaces may provide a vector with PIV surviving on surfaces for 
up to 10 hours108. The respiratory epithelium appears to be the major site of 
viral replication with cytokines such as IL-2, IL-6 and IL-10 being detected in 
elevated levels in samples from PIV positive patients111. Research into specific 
targets for prevention and treatment of PIV is ongoing but has produced 
positive results. Development of a vaccine for PIV has been discussed by a 
group from the USA, with PIV-3 being the most likely target but the limitation to 
one sub-type has raised questions on impact if this were to be created and 
development has not been forthcoming 110. 
 
1.3.7  Coronavirus: 
 
 Coronaviruses (CoV) are enveloped positive single stranded RNA 
viruses of the family Coronaviridae84. CoV are divided into 3 subgroups which 
are then further subdivided, groupings are based on serological and genetic 
analysis and are called Group 1/2/3112. Many of the groups of coronaviruses 
however do not infect humans. Human infection and transmission has been 
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described in five subtypes – HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-
OC43 and novel SARS-CoV112. The discovery of CoV was relatively early 
compared to many other respiratory viruses, in the 1960’s. However the study 
of these viruses has increased greatly in recent years after the emergence of a 
novel coronavirus in 2002 that caused acute respiratory symptoms and 
exhibited pandemic spread– severe acute respiratory syndrome (SARS)113.  
The reason for limited research into CoV prior to this was because only 
two human CoV had then been described (HCoV-OC43 and HCoV-229E)112. 
These two viruses were known to cause URTIs but not LRTIs, except in elderly 
immuno-compromised patients112. However the novel strain found to cause 
SARs was involved in severe LRTI and demonstrated rapid spread. It was 
reported to cause 8098 human infections of which 774 resulted in mortality 
(10%) and spread to 32 countries during the pandemic113. The novel virus was 
found in animals including civet cats and raccoon dogs, although the source of 
transmission is thought to be bats114. 
 Since the SARS pandemic two new subtypes, HCoV-NL63 and HCoV-
HKU1 have been isolated from hospitalised children with severe respiratory 
disease113. CoV has also been shown to be detected in 4-10% of childhood 
ARI47 115. Transmission of CoV is by aerosol means and findings from the 
SARS pandemic showed that transmission did not occur until after symptoms 
had began to appear, adding to the effectiveness of quarantine and 
containment procedures112. Transmission from animal to human is also a great 
area of interest with the majority of CoV virus family infecting animals and 
capable of causing severe multi-organ disease, it is thought SARS was 
transmitted this way112 113. Studies into the immunological response of CoV-
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SARs have been carried out and demonstrate a Th-1 response with elevated 
levels of interferon as well as a variety of inflammatory cytokines and 
chemokines including IL-6, IL-8 IL-10 and IL-2112. Due to the severity of the 
SARS pandemic a target treatment for CoV or vaccine has been a publicised 
goal but remains elusive with no effective method for vaccination being 
highlighted113. 
 
1.3.8  Influenza: 
 
 Influenza virus is an enveloped, single stranded negative RNA virus of 
the family Orthomyxoviridae. Influenza viruses are divided by groups with the 
three types being influenza A, influenza B and influenza C. All influenza A 
viruses express haemagglutinin (H) and neuraminidase (N) antigens upon their 
surface which are used to sub classify the virus with 16 H subtypes (H1-16) 
and 9 N subtypes (N1-9)116. Influenza B viruses also demonstrate mutation but 
to a lesser extent, and influenza C viruses are rare and of little clinical 
significance. The influenza A group of viruses are by far the most common and 
are responsible for the seasonal epidemics of influenza infections117. The 
genome of all influenza viruses are highly plastic and susceptible to point 
mutations, this is demonstrated in influenza A viruses that regularly show 
changes in their H and A molecules. These mutations change seasonally 
altering the ability of the virus to evade a hosts immune system, this 
phenomenon is described as “antigenic drift”117. However periodically dramatic 
alterations in influenza A antigens are observed, usually every few decades. 
Significant changes in antigen expression results in increased susceptibility of 
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the population to influenza infection and results in distinctly different antigenic 
character of influenza virus termed “antigenic shift”117. This characteristic 
mutation in antigens has also allowed influenza to pass between species in the 
past with avian and swine transmission leading to novel influenza subtypes.  
 Seasonal influenza is traditionally seen each winter time and represents 
a large population burden. This is especially true in children, between 1997 
and 2001 attack rates of children presenting with influenza-like-illness in the 
USA ranged from 58 to 90 cases per 100 children in those under five years, 23 
to 52 per 100 for those aged between 5 and 11 years and 13 to 27 per 100 in 
those aged 12 to 17 years118. In all age groups in the USA it is estimated the 
direct healthcare cost of influenza A is $10 billion and the burden on USA 
economy is $87 billion a year119. Morbidity and mortality is most significant in 
the young and elderly persons or those with underlying conditions or chronic 
medical conditions, the average mortality each year in the USA is 51,000117. 
Influenza infection can cause a spectrum of disease severity varying from a 
mild URTI to fatal pneumonitis, although severe disease is much rarer than 
mild disease117.  
 Unlike many other viral respiratory infections, treatments are available 
for severe influenza infection. Traditional antiviral medications such as 
amantidine and rimantadine can be used for patients that present to hospital 
with severe acute symptoms, within 48 hours of onset however are not usually 
the current treatment of choice117. Neuraminidase inhibitors are preferred as 
they have been developed for specific treatment of influenza, however they are 
costly and their use is limited to high risk patients such as pregnant women or 
those with co-morbidities117. Oseltamivir is an example of a commonly used 
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neuraminidase inhibitor that has proven effective in severe influenza infection, 
including novel H1N1 influenza120. Other examples of neuraminidase inhibitors 
include zanamivir, lininamivir and permaivir121. One of the most effective 
means of reducing the population burden of influenza has been the adoption of 
seasonal vaccination to high risk groups in many developed countries. 
Vaccines utilise both inactivated and live attenuated strains of influenza and 
the most effective choice has varied in the literature, as well as depending on 
patient age and demographics122. Guidelines are updated regularly by the 
centre for disease control and prevention (CDC) in America where currently 
vaccination is recommended in children aged 6 months – 18 years, adults over 
50 and anybody with high risk conditions117. In the UK the Department of 
Health (DoH) recommends vaccination in high risk groups which include; age 
over 65, chronic respiratory/ heart/ kidney/ liver/ neurological disease, 
diabetes, immunosupression, pregnancy, people in long stay residential 
homes and carers123. Each year the vaccine is altered and contains three 
strains of influenza that are selected to be the most likely to circulate the 
following influenza season122.   
 Novel strains of influenza that have been formed by antigenic shift 
represent new challenges to influenza management. These strains have the 
ability to spread rapidly and can easily reach pandemic levels. Novel strains 
can represent altered clinical presentations of influenza or increased severity 
of clinical manifestations. The first recorded pandemic was the 1918-1919 
“Spanish” influenza (H1N1 subtype) that killed approximately 50 million people 
worldwide with mortality rates of 2.5%116. Similar pandemics have occurred 
regularly since then, with the “Asian” influenza of 1957 (H2N2 subtype), “Hong 
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Kong” influenza in 1968 (H3N2 subtype) and “Russian” influenza (H1N1 
subtype) of 1977116.  
Most recently, in the spring of 2009, antigenic shift was once again 
observed in influenza virus of H1N1 subtype when a novel influenza virus 
(H1N1) appeared in Mexico causing cases of severe viral pneumonitis103. This 
strain rapidly spread throughout the world and by June 2009 the WHO 
declared that this novel influenza virus had reached the level of global 
pandemic124 125. This newly formed virus was thought to be a product of four 
previously known strains of influenza A one from humans, one from birds and 
two from swine origin126.  Early on in the pandemic it was shown that children 
were more likely to suffer with infection and over sixty percent of cases in the 
US were patients under the age of eighteen127. The severity of the infection 
has also been found to be greater in children. An age of less than five years 
being a high risk factor for severe illness, and risk was especially high if under 
two years of age128. Other comparable risk factors included age greater than 
65 years, pregnancy or pre-existing medical condition128. This novel pathogen 
represented a large burden on healthcare, estimated to cause 59 million 
illnesses and 265,000 hospitalisations in the USA126. These features were also 
reflected in UK data where hospitalisation was highest in those aged <5 years 
and 59% of in hospital deaths occurred in previously healthy patients129. These 
findings together highlight novel H1N1 as an important pathogen in paediatric 
ARI. 
 In summary influenza represents one of the most common and also one 
of the most variable viral respiratory pathogens involved in ARI. Its predictable 
seasonal nature has led to developments in vaccination and prevention which 
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have helped to reduce burden. However significant shifts in antigen structure 
can lead to varying clinical presentations and severity of this pathogen, most 
recently demonstrated by the novel H1N1 pandemic. 
 
1.3.9  Bacterial infections: 
 
 This study mainly focuses on the viral pathogens that cause ARI in 
children. Bacterial infection is also an important cause of many types of ARI. 
Research into bacterial causes of ARI has been ongoing for a greater length of 
time than viral studies, mainly due to the techniques of culturing bacteria for 
investigation.  
 The most common bacteria detected in paediatric airways is 
Streptococcus pneumoniae (pneumococcus). It was first characterised more 
than a century ago and has always been linked with respiratory disease57. 
Pneumococcus is commonly found in the upper respiratory tract where it is not 
associated with disease, however spread to the lower airway can result in 
severe clinical manifestations of ARI especially pneumonia57. It is also 
associated with meningitis and septicaemia, leading to an estimated worldwide 
mortality of between 700,000 and 1 million children each year130. Similar to 
other pathogens of ARI these deaths are significantly higher in the developing 
world with the majority being in Africa of Asia131. Significant developments in 
treatment and prevention of invasive pneumococcus disease have been made 
in recent year. Development of a vaccine (firstly polysaccharide and more 
recently developed into conjugate) and its utilisation worldwide have reduced 
 33 
mortality, with estimates suggesting proportions of deaths from pneumococcus 
has declined from 36% to 26% worldwide130. Newer versions of the conjugate 
vaccine are also being introduced with varieties of vaccine preparations 
available that target different serotypes of pneumococcus, continued research 
is ongoing to the impact of vaccination strategy and whether elimination of 
common strains may allow more unusual serotypes to the airway132. 
 Although pneumococcus is the most common bacterial pathogen 
involved in paediatric ARI, Hib is also a common pathogen. Together 
pneumococcus and H. Influenzae are estimated to be involved in 50% of 
childhood pneumonia in the developing world53. H. Influenzae is estimated to 
cause 371,000 childhood deaths worldwide being involved in the pathology of 
pneumonia and also epiglottitis56. Similarly to pneumococcus however a 
conjugate vaccine has been developed since the 1990s (after the 
polysaccharide vaccine showed only modest impact in the 1980’s) which has 
shown promising results worldwide. The H. Influenza conjugate vaccine (Hib) 
has demonstrated to be have high efficacy and be cost effective56. Vaccination 
for both pneumococcus and H. Influenzae has been highlighted as high 
priorities for widespread use in the developing world in order to achieve the 
millennium goals of paediatric mortality reduction. Use of Hib vaccine is more 
widespread worldwide than pneumococcus having been recommended by 
WHO in 2005 and Pneumococcus in 2008133. 
 Much literature focuses on the impact of ARI caused by pneumococcus 
and H. Influenzae infection with many well documented reports on its 
worldwide epidemiology. This is understandable due to their common 
occurrences. However, many other bacteria have been associated with ARI, 
 34 
especially pneumonia. Infections such as the fungi Pneumocystis jirovecii or 
the bacteria Mycoplasma pneumoniae, Chlamydia trachomatis and 
Chlamydophila pneumoniae have all been shown to be involved with paediatric 
ARI with comparatively less known than the two most common pathogens. The 
impact of these atypical bacterial pathogens varies in different studies on ARI 
and also with conditions the child may have such as HIV53. Research into 
these less common pathogens is important as the more common bacteria have 
shown treatment and vaccination strategies to be an effective method of 
targeting bacterial disease. The interaction of pneumococcus with other 
respiratory pathogens is also an area of research interest. Especially its 
interaction with viral pathogens as some studies have suggested an increased 
severity with pneumococcus and viral respiratory infection134 135. 
 
1.3.10  Other pathogens and novel pathogens: 
 
 Despite ARI being recognised for a significant amount of time as one of 
the leading causes of childhood mortality worldwide, pathogen classification is 
still incomplete. Novel pathogens have been discovered with the development 
of new detections techniques. Examples of this include hMPV and hBoV which 
were discovered as recently as 2005 and are difficult to cultivate in a viral 
culture model101. The spectrum of pathogens involved is also further 
complicated by mutations and developments in previously defined viruses that 
lead to novel clinical manifestations, such as the CoV that caused SARs and 
novel H1N1 influenza136. These pathogens can mutate de-novo or also can be 
transmitted from animal hosts, raising the potential for new infections. Co-
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detection of pathogens is also common which brings into question the role of 
different infective agents, and whether they are causative in ARI, present as a 
coincidence or if there is interaction between two pathogens that can cause 
pathology.  
 Overall no study has purported to detect all pathogens in individuals 
presenting with ARI. There are still questions raised about previously 
discovered pathogens and it remains important to fully assess novel 
pathogens after their emergence.   
 
1.4 Risk factors for ARI: 
 
 There are a number of recognised risk factors that increase both the 
probability of suffering ARI and the likelihood of severe infection. Recognised 
risk factors of both bacterial and viral infections have led to development of a 
targeted approach to prevention of disease. Children and adults with risk 
factors can be selected for vaccination regimes or preventative treatments to 
decrease overall disease burden of ARI. 
Frequency of ARI correlates closely with age, children being much more 
likely to be infected than adults. It is estimated that children suffer 6-8 
respiratory infections a year compared to 2-4 in adults96. The majority of these 
infections are mild and confined to the upper airway, resolving without 
presentation to a healthcare professional. However, each one of these 
infections has the potential to progress into a more severe clinical presentation 
or systemic illness. There are also observable differences in children that occur 
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with age, with infants under 2 being at especially high risk of severe LRTI due 
to the small calibre of their airways and their naivety to viral infections once 
maternal antibody has wained137. 
Previous respiratory and cardiovascular pathology is also associated 
with increased risk of severe ARI. In children conditions such as asthma or 
Cystic fibrosis can increase the likelihood of respiratory infection, whereas in 
adulthood chronic obstructive pulmonary disease (COPD) can increase risk of 
hospitalisation with ARI2 129. Pulmonary hypoplasia is a recognised as a risk 
factor for severe viral infection, especially RSV disease in infancy, it also 
correlates closely with prematurity which also is recognised to be associated 
with ARI138.  
Worldwide distribution of ARI severity is also skewed towards the 
developing world, especially Africa and Asia. It is estimated 70% of ARI burden 
is represented by the developing world with the majority of pneumonia 
mortality worldwide being present in 42 countries2 139. There are multiple 
reasons for this including lower levels of vaccination and reduced availability of 
hospital care2 60. Vaccination levels for Hib and Pneumococcus are lower in the 
developing world due to problems with cost and distribution, however 
international organisations such as WHO and the Global Alliance for Vaccines 
and Immunisation (GAVI) in recent years have aimed to make these more 
accessible133. Two highly prevalent conditions in the developing world, 
especially Africa, are malaria and human immunodeficiency virus (HIV). Both 
of these are associated with increased severity of ARI and it has been reported 
that malaria may cause underreporting of ARI mortality due to misdiagnosis131. 
Immunodeficiency is a well documented cause of increased ARI susceptibility 
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with the most common reason worldwide being HIV, infection with HIV can 
also allow infection with novel infections which are rarely seen in immuno-
competent patients e.g. Pneumocystis jiroveci which pose treatment difficulties 
for physicians due to the immunocompromised patients relative inability to 
clear infections140. Malnutrition is also an important factor which is more 
prevalent in the developing world and is associated with increased severity of 
ARI and increased risk of mortality in children141. In the developing world it is 
also much more prevalent to cook with biomass fuels in an enclosed indoor 
setting, which is associated with increased risk of ARI142. 
Lifestyle factors can also affect a child’s risk of ARI. The most 
recognised factor is parental smoking, both during pregnancy and infancy. It 
has been shown that parental smoking is associated with increased frequency 
of respiratory infections as well as higher prevalence of adolescent asthma, 
wheeze, middle ear infection and reduced lung fuction143. In the post-natal 
period environmental tobacco exposure causes airway release of pro-
inflammatory cytokines and induces hyper-reactivity143 144 A second suggested 
explanation is prenatal smoking being associated with other ARI risk factors 
such as prematurity and reduced birth weight143. A household environment 
with postnatal smoking is also associated with respiratory infections and 
asthma in the absence of prenatal smoking143. 
Finally certain combinations of respiratory infections have been shown 
to produce more severe ARI in children. These findings are much debated in 
the literature but one combination that is agreed upon is influenza infection in 
the presence of pneumococcus infection145. The interaction of respiratory 
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pathogens increasing risk of severe ARI is important as it further highlights the 
need for full assessment of pathogens present during ARI. 
 
1.5 The treatment and prevention of ARI 
 
 Interventions to reduce the burden of paediatric ARI have involved both 
the acute management of the child and preventative measures such as 
vaccination strategies. Vaccination has become available for a number of 
pathogens involved in ARI, some of which are accessible worldwide. The most 
widely used vaccines for ARI pathogens are Hib, pneumococcus and 
influenza2. Conjugate Hib vaccine is effective in reducing prevalence of both 
pneumonia and meningitis caused by infection, both in industrialised countries 
and also in developing countries146. All studies have shown the vaccine to 
protect in greater than 90% of cases, resulting in conjugate Hib vaccine being 
utilised in all industrialised countries as part of routine childhood vaccination 
schedule2. Various preparations are available and the Hib vaccine is often 
included with other preparations to immunise against multiple pathogens in on 
injection e.g. diphtheria, tetanus, polio. In the UK vaccination schedule four 
doses of Hib are given at 2, 3, 4 and 12-13 months147. In contrast Brazil gives 
four doses at 2, 3, 4 and 6 months148. Interestingly the Hib vaccine was initially 
developed to target invasive meningitis, but has also shown to reduce 
childhood pneumonia hospitalisations by 20 – 30%2. 
 Pneumococcal disease is one of the most commonly detected bacterial 
pathogens in childhood ARI. A number of vaccines are available for this 
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bacterium which target differing numbers of strains. In the UK the conjugate 
13-valent preparation is part of the vaccination schedule and is administered at 
2, 4 and 12-13 months147. Previous preparations of the vaccines were shown 
to be highly effective in both developed world and developing world, with 59% 
reduction in LRTI mortality in children under five by use of the polysaccharide 
vaccine2. However vaccine coverage is not currently included in every country. 
Brazil has very recently added the conjugate pneumococcus vaccination to the 
childhood vaccination schedule with the main limitation being cost and 
economic assessment being necessary before uptake56 149 150. 
 Influenza vaccination is not utilised as frequently as the previous two, 
mainly due to costs. The CDC recommended during the H1N1 pandemic that 
all children between 6 months and 18 years and adults over 50 should be 
universally vaccinated117. However cost and vaccine shortages meant that this 
was not achieved or attempted in many countries. Influenza vaccination does 
not form a part of standard childhood immunisation in UK or Brazil. High risk 
groups may however be targeted for vaccination, these include many risk 
factors mentioned previously but in children reasons may be chronic medical 
conditions, prematurity or immunosupression such as HIV117. 
 Acute management and treatment of individual presentations of ARI is 
usually dependent on diagnosis. Many URTIs are self limiting and may not 
present to a physician, also with the majority being viral treatment options are 
limited. Bacterial infections for diagnoses such as tonsillitis or otitis media may 
highlight the need for antibiotics, but it is difficult to ascertain with certainty 
whether a bacterial or viral pathogen is implicated although tools such as the 
Centor criteria have aimed for clarification(where fever, tonsillar exudates, 
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cervical lymphadenopathy and absence of cough are suggestive or bacterial 
infection requiring empirical antibiotic treatment)18. Pneumonia has been the 
target for guidelines produced by the WHO to reduce mortality in the 
developing world. WHO clinical guidance has highlighted that the diagnosis of 
pneumonia is likely based on rapid breathing and chest wall in-drawing, 
allowing the diagnosis to be made in the absence of radiological investigation2. 
The choice of treatment is then made on the evidence that the majority of 
bacterial pneumonias are caused by S. pneumoniae or H. Influenzae and so 
penicillin based antibiotic is first line treatment, by oral route if mild or 
intramuscular route if severe2. Other measures for both pneumonia and ARI in 
general are supportive, with correction of fluid balance and hypoxia being 
primary targets2 (Figure 1.1). 
 
1.6 The global burden of acute respiratory infections in 
children 
 
 ARIs represent a large worldwide burden in paediatric mortality and 
morbidity. The burden of individual diagnoses that constitute ARI have been 
mentioned previously. WHO data recognises ARI as the largest identifiable 
cause of mortality in children under 5 years, accounting for 19% of deaths, 
higher than both malnutrition and malaria deaths in this age group (Figure 
1.3)1. This equates to an estimated 3.9 million deaths per year, with some 
opinions suggesting this may be an underestimate due to misdiagnoses such 
as malaria and variable definitions of ARI being used for classification1 131 151. 
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The burden of mortality is significantly higher in the developing world with 70% 
of ARI mortality in Africa and South East Asia and the majority of deaths 
occurring in 42 countries of the world151 152. Reasons for this include lower 
vaccination coverage and reduced access to healthcare2. The most common 
diagnosis to result in mortality is pneumonia2. 
 ARI morbidity is also significant worldwide. WHO estimates ARI to 
cause over 94 million disability adjusted life years (DALYs) worldwide in all age 
groups153. The majority of pneumonia cases do not result in mortality and in 
developing countries more than 25% of children will suffer pneumonia each 
 
1.7 Diagnostic methods for Acute Respiratory Infections 
 
 In the past much viral and bacterial diagnostics were done by culturing 
techniques, growing pathogens collected from patient samples in a controlled 
environment. This method was more effective in bacterial diagnosis which 
could be viewed on microscopy. However for viruses many additional stages 
were involved including antibody staining and washing, viruses also were 
generally more difficult to cultivate and often resulted in negative samples or 
contamination95. Large studies into viral epidemiology were therefore 
unrealistic with high negative rates and laborious methodology.  
Immunofluoresence assay are one method of detecting viral pathogens 
in respiratory infection. This method is divided into indirect and direct 
immunofluoresence where an indirect assay requires a secondary antibody 
and is processed in a lab. More recently developed immunofluoresence kits 
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have the fluorescing antibody attached to the primary kit and can be 
administered at the point of care154. Both of these techniques are faster and 
more reliable than viral culturing techniques, however are more expensive. 
Cost is less than RT-PCR and unlike RT-PCR a dedicated virology centre is 
not necessary. Immunofluorecent tests are available for a variety of pathogens 
including RSV, hMPV and influenza154-156. In direct comparison studies have 
shown RT-PCR to be more sensitive than direct florescence however 
sensitivity is higher than cell culture techniques155 156. Detection of multiple 
pathogens is not possible with direct fluorescence and kits are not available for 
all viral pathogens, they are also costly and a large number would be required 
to screen for multiple pathogens and so they are not appropriate in this study. 
Since the turn of the century the use of polymerase chain reaction 
(PCR) has become widespread in viral diagnostics. The process represented a 
significant research breakthrough earning a Nobel prize in 1993157. The 
process of PCR aims to replicate the process of a normal cell cycle in a 
controlled environment with the aim of amplifying genetic material158 . The 
three stages of thermal denaturation, primer annealing and primer extension 
allow identical copies of genetic material to be made, with selective 
amplification possible due to the design of primers (Figure 1.2) 158. Use of  
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Figure 1.1: A child receiving nasal CPAP for bronchiolitis in Recife, Brazil.  
An example of acute ARI management (Photo taken by Dr Paul McNamara 
and used with permission) 
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Figure 1.2: (taken from Garcia et al159) “Three steps in polymerase chain reaction 
(PCR) and real-time PCR.” 
 Step 1, Denaturation: Template DNA mixture is heated to 90–95°C, allowing 
the DNA double strand to denature and separate into two single strands. Step 
2, Annealing: Template DNA mixture is cooled to 50–60°C to allow primers (for 
PCR) and primers plus the TaqMan probe, which consists of an 
oligonucleotide with a 5-reporter dye (R) and a downstream, 3-quencher dye 
(Q) (for real-time PCR), to anneal to the single-stranded DNA. Step 3, 
Extension: The temperature is raised to 72°C to allow Taq polymerase to add 
deoxynucleotides to the target DNA (for PCR) and complete the amplification. 
For real-time PCR, the TaqMan probe containing a reporter dye at the 5 end 
and a quencher dye at the 3 end is separated on cleavage by DNA 
polymerase, resulting in increased fluorescence of the reporter as well as the 
newly amplified target DNA. These three steps are repeated 30–40 times to 
replicate 2n copies of DNA region of interest where n = cycle number.”159 
 45 
fluorescence in PCR primers can allow quantification of genetic material in 
comparison to known “housekeeping” genes expressed in samples. Further 
developments in PCR have allowed multiple sections to be analysed 
simultaneously in one sample with separate wavelengths being indicative of 
specific sections – multiplex PCR160. Overall these developments have allowed 
new insights to viral infections, with rapid and sensitive analysis being possible 
of large numbers of samples. Utilisation of PCR techniques is costly though, 
especially the machines which make high throughput analysis possible. Due to 
the expense the utilisation of PCR is limited worldwide, especially in the 
developing world. 
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Figure 1.3: Worldwide mortality causation data in children <5 years (WHO data 
2010)1 
 
 
 47 
year throughout the first five years of life53. Overall 2-3% of all children have 
pneumonia severe enough to require hospitalisation53. URTIs are also highly 
prevalent in this age group and have the potential to progress to significant 
disease. Children are estimated to experience 4-8 upper respiratory infections 
a year, twice as many as adults88. Mortality is rare with URTIS but they are still 
a common cause of morbidity. Even in developed countries URTIs are 
estimated to cause 20 million days of absence from work and 22million days of 
absence from school in the USA alone96. 
 
1.8 Pulmonary immune response to ARI: 
 
 The immune response to infection is an important aspect of pathology in 
ARI. The immune response to infection in the lung is vitally important, with 
many respiratory pathogens causing pathology due to the inflammation and 
mucus production that is caused by the immune system clearing infection. 
Classically the immune responses to all infections are divided into the innate 
and adaptive immune systems. The effector mechanisms of the innate immune 
system include antimicrobial peptides, phagocytes, alternative complement 
pathway as well as natural barriers such as the skin161. These mechanisms 
can be activated rapidly in response to a pathogen, immediately after its 
detection.  
The innate immune response is non-specific compared to the adaptive 
immune response, with pattern recognition receptors in non-self pathogens 
being detected and triggering the innate immune system to respond 
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immediately while recognising self molecules and not responding. Activation of 
an innate receptor can mediate a number of functions, including phagocytosis, 
release of chemoattractant substances or release of effector molecules that 
initiate the adaptive immune response162. Receptors of the innate immune 
system are germ-line encoded and therefore limited, this means the function if 
to recognise receptors that are found on common pathogens and are 
widespread161. These “pattern-recognition receptors” are expressed on the 
effector cells of the innate immune system which include macrophages, 
dendritic cells and B cells. The best characterised receptor is mannan-binding 
lectin161. Toll like receptors (TLRs) are also an important range of receptors 
involved in innate immunity.  
 In contrast the adaptive immune response produces a highly specific 
response targeted at an individual pathogen. The main cell classes involved in 
adaptive immunity are T cells and B cells. It takes time for this response to be 
activated, three to five days, and so highlights the importance of overlap 
between the innate and adaptive response. The receptors of the adaptive 
immune response differ to that of the innate system. Receptors for the innate 
system are coded for in the germline genome of the cell limiting their potential 
range. Whereas cells of the adaptive immune systems receptors are produces 
from a large array of gene segments, arranged in different sequences and that 
then undergo a process of somatic recombination to increase variability163. 
Once a receptor binds to a complimentary pathogen, which must be presented 
to T cells by an antigen presenting cell (APC) or a major histocompatability 
complex (MHC) protein on the cell surface, the adaptive immune cell replicates 
rapidly to produce numerous identical cells with similar complimentary 
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receptors – the process of clonal expansion163. B-cells are involved in the 
production of antibodies which are important for increasing uptake of pathogen 
by phagocytotic cells and causing agglutination of pathogen molecules. T cells 
are further subdivided by role into T helper cells, cytotoxic T cells, memory T 
cells, regulatory T cells, Natural killer T cells and γδ T cells. They can also be 
divided by their expression of the surface proteins CD4 and CD8163. The 
surface protein is important for T cell function as it defines which class of MHC 
the cell can bind to, CD8+ T cells bind to class I MHC cells which are 
expressed on the surface of almost all cell types and can express endogenous 
antigen, such as virus, within the cell. CD4+ T cells in contrast bind to MHC 
class II receptors which are present on APCs and inducible by stimuli from the 
innate immune response e.g. TLRs163. 
 The largest group of T cells within the body is the T-helper subclass 
(Th)163. These cells play a vital role in directing immune response by secreting 
a range of cytokines that can increase or regulate specific aspects of immune 
response. Cytokines can be defined as “a diverse group of protein signal 
molecules that are produced by a wide variety of cells, they activate or 
influence adjacent cell movement differentiation, growth and death”164. In 1986 
it was found that not all Th cells expressed identical types of cytokines and 
with analysis demonstrating two distinct groups; T-helper 1 cells (Th-1) and T-
helper 2 cells (Th-2)165. Th-1 cells were characterised by expression of 
interferon gamma (IFN-γ) whereas Th-2 cells expressed interleukin 4 (IL-4) 
which was important in inducing immunoglobulin E (IgE)165. Both IL-4 and IgE 
were found to be elevated in asthmatic and atopic patients leading to the 
hypothesis that and imbalance between Th2 and Th1 helper cells was 
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important in the generation of asthma in children164-166. More recently the 
discovery of new cytokines (e.g. IL-17) which were not explained by the 
Th1/Th2 classification led to re-evaluation of the classification of Th cells. It 
has since been shown that numerous other Th cells are present which 
differentiate in response to the presence of specific cytokines and express 
individual cytokines respectively (Figure 1.4)163.  One subclass of T-helper 
cells that have gained special attention is the T-helper 17 (Th-17) cells which 
have been shown to play an important role in linking the adaptive and innate 
immune system, they have also been demonstrated to play a role in 
autoimmune diseases including rheumatoid arthritis165. This study aims to 
assess the role of IL-17 in RSV infection, an important infant infection that is 
associated with asthma and wheeze in later life. 
 
1.9 Work that has led to this study 
 
 Previous work by Dr Katie Rose (MPhil student 2009/10) highlighted the 
importance of viral pathogens in paediatric ARI in Brazil. In collaboration with 
the Instituto Materno-Infantil Professor Fernando Figueira (IMIP) Children’s 
Hospital, Recife, North Eastern Brazil, her findings on the viral and atypical 
bacterial epidemiology of children <5 presenting to hospital with ARI over a 
one year period have been published167. This publication documented the 
prevalence of pathogens in this cohort and showed that a pathogen could be 
detected in 86% of samples, the most prevalent pathogens being RSV, AdV, 
hRV and hBoV (Figure 1.5167). This manuscript also highlighted the extent of 
co-infection in this group and characterised the pathogens involved (Figure 
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1.6)167. Through continuation of this previous work we hope to further 
characterise the pathogen epidemiology in this group, specifically with regard 
to H1N1 and hRV. 
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Figure 1.4: (taken from Bonilla et al163) “ CD4+ TH cell subsets.” 
 Antigen-specific naive TH0 T cells are stimulated to expand on interaction with 
APCs expressing MHC class II/peptide complexes. Depending on the type of 
APC and the cytokine milieu (arrows) at the site of antigen encounter, TH0 cells 
can be driven down one of several differentiation pathways. The 
TH populations that arise retain the TCR specificity of the parent TH0 cell but 
secrete unique constellations of cytokine products that mediate distinct effector 
functions, including activation for killing of microbes (TH1), production of 
antibodies and expulsion of helminths (TH2), induction of inflammatory 
responses (TH17), and dampening of immune activation (regulatory 
T [Treg] cells). Specific transcription factors (indicated in the nuclei) stabilize 
lineage commitments and dictate the specific cytokine secretion 
profiles. FoxP3, Forkhead box protein 3; RORγt, (retinoic acid receptor related 
orphan receptor γt); STAT3, signal transducer and activator of transcription 
3; T-bet, T-box expressed in T cells.”163 
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Figure 1.5: (Taken from Bezerra et al167) “Pathogen prevalence (%) in 
nasopharyngeal aspirates from children less than five years with acute 
respiratory infection.” 
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Figure 1.6: (Taken from Bezerra et al167) “Pathogen frequency in singly 
infected (red) and co-infected (pink) nasopharyngeal aspirate samples.”  
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1.10 Aims and objectives of this study: 
 
 This MPhil thesis describes three discrete studies, all investigating 
different aspects of viral and atypical bacterial ARI in paediatric patients. The 
titles/aims of these studies are as follows: 
 
An investigation into the causes of childhood ARI and the impact of 
H1N1 influenza 
Aims: 
 1) To characterise the viral and atypical bacterial pathogens detected in 
children <5 years presenting to hospital in Recife, Brazil.  
2) To characterise the clinical and demographic features of children suffering 
H1N1 infection compared to non-H1N1 ARI. 
 
An investigation into the prevalence of Rhinovirus-C in paediatric acute 
respiratory infection 
Aim: 
1) To describe the role of the novel hRV group, hRV-C, in paediatric ARI.  
  
An investigation into the interaction between Interleukin 17, Interleukin 
13 and RSV infection in airway epithelial cells  
Aim: 
1) To determine the role of interleukin 17 (IL-17) in RSV infection of airway 
epithelial cells and measure for synergy with IL-13.  
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2 An Investigation into the causes of childhood 
ARI and the impact of H1N1 Influenza 
 
2.1 Introduction 
 
ARI represents the largest single identifiable cause of mortality in children 
under five years old worldwide accounting for 19% (3.5 million) of identifiable 
mortality, the vast majority occurring in just 42 coutries152 49. ARI has been 
defined in Section 1.1.  
 Despite such a large global burden, some studies have suggested 
initiatives to reduce ARI impact have been met with limited success and ARI 
remains the largest cause of childhood mortality152. The pathogenic causes of 
ARI have been studied, but previous techniques made this a slow and 
laborious process168. New techniques such as reverse transcription 
polymerase chain reaction (RT-PCR) have now made it possible to analyse a 
range of pathogens simultaneously with high specificity. It has also facilitated 
discovery of newer pathogens (e.g. hMPV, hBoV)106. These techniques are 
however rarely available in the developing world. 
 There is still much that is unknown about the interaction between 
respiratory viruses in the airway and how they cause symptoms/signs of 
childhood ARI. Some viruses, e.g. RSV, have been studied in detail but more 
novel viruses are less defined or rarely included in studies. Epidemiological 
studies do not identify a pathogen in all cases of ARI, many report positive 
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rates of 35%-47%169-171. Further complexity is encountered when multiple 
pathogens are detected on analysis, causing confusion as to which pathogen 
is the cause of the acute episode or if there is interaction between multiple 
pathogens. 
 There is much heterogeneity between studies into paediatric ARI 
epidemiology. RT-PCR has allowed analysis of ARI pathogens in a number of 
publications. However, the choice of pathogens, age of participants, clinical 
inclusion criteria and sampling methods have tended to vary (Table 1.1). There 
are few studies of this nature in Brazil or South America. This study follows on 
from the first year’s results into paediatric ARI epidemiology in Brazil previously 
documented by her MPhil studies in 2009/10. Her publication in PLoSOne 
described a high level of pathogen detection (87%) and highlighted the 
importance of co-infection in this population(39%)167.  
Pathogens are also capable of mutation, changing their clinical 
properties. Children suffer 6-8 respiratory viral infections a year compared to 2-
4 in the average adult, making novel pathogen emergence especially important 
in this group96. Recently a novel strain of H1N1 influenza A (H1N1) emerged. 
First identified in April 2009 in Mexico, H1N1 rapidly spread throughout North 
America127. In June 2009 the WHO issued a pandemic alert on H1N1127. Initial 
reported cases of H1N1 presented with viral pneumonitis caused severe 
respiratory distress116. Demographic and epidemiological data demonstrated 
children, especially those under age five, were at high risk of severe disease 
and accounted for 18% of hospitalisations126 127.  
 With the burden of ARI burden being so great in children it is important 
to fully document the pathogens involved and to fully assess novel pathogens. 
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This study aims to assess the pathogens involved in children under five 
presenting with ARI to a paediatric A&E in Recife, North East Brazil. Two thirds 
of children in Recife live in slum or favela population and viral diagnostic 
techniques are not usually available. Following on from the first year of this 
study, RT-PCR for 18 pathogens was performed on samples collected over 
two years (2008-2010). The timing of this study had the unique fortune of 
covering the emergence of H1N1 influenza and so the secondary aim was to 
assess the impact of the H1N1 pandemic on ARI presentations in this cohort. 
 
Table 2.1: An overview of studies into viral ARI epidemiology.  
Study Bezerra
167
 Berkley
47
 Wang
115
 Do
172
 Jartti
173
 Singleton
174
 Sung
169
 Kaplan
175
 
Country Brazil Kenya Shanghai Vietnam Finland USA  (Alaska) Hong Kong Jordan 
Age Group <5 years <12 years <9 years <15 years  <16 years <3 years <5 years <5 years 
Setting A&E Admission Outpatient Admission Admission Admission Admission Admission 
ARI included All ARI Pneumonia All ARI All ARI Acute wheeze LRTI All ARI All ARI 
Sample method NPA Nasal Wash Swab Swab + NPA NPA Swab NPA + Swab NPA 
Length of Study 12 months 12 months 24 months 35 months 20 months 24 months 12 months 6 months 
N 407 759 817 309 293 440 475 326 
Median age 8 months 7 months 36 months 24 months 19 months 64% <1 year 24 months 5 months 
Detection: 87% 56% 60% 72% 88% 90% 47% 78% 
RSV 37% 34% 19% 24% 27% 23% 8% 43% 
AdV 25% 4% 7% 5% 5% 30% 5% 37% 
hBoV 19% 2% 19% 16% - - - 18% 
hRV 19% - 12% 4% 24% 44% 4% 11% 
hMPV 10% 3% 7% 7% 4% 15% 2% 3% 
PiV 4% 8% 13% 7% 6% 18% 9% 0 
Mpp 10% - - - - - 2% 0 
Flu 3% 5% 17% 17% 2% 5% 10% 1% 
CoV 3% 10% 4% 8% 1% 6% 4% 1% 
Cpp 1% - - - - - 0% - 
Co-infection: 39% - 14% 20% 19% - 4% 22% 
2.2 Methods 
 
This chapter details the methods used to identify respiratory pathogens 
present in the airways of children presenting with ARI. These findings include 
the second year of a project into this topic with the findings of the first year 
recently published167. 
 
2.2.1  Patient Recruitment 
 
Patient recruitment took place in the emergency department at the Instituto 
Materno-Infantil Professor Fernando Figueira (IMIP) Children’s Hospital, 
Recife, North Eastern Brazil between April 2008 and March 2010.  
Children below the age of five, presenting to the accident and emergency 
department with signs or symptoms of ARI lasting less than seven days were 
eligible for inclusion. This included both upper respiratory and lower respiratory 
presentations. Patients were excluded if they had been re-admitted within the 
course of the same infection or had cyanotic heart disease. Participants were 
included whether they did or did not require hospital admission. 
Consent was obtained from all participants parents before recruitment. 
Ethical consent was obtained both from the IMIP ethics committee and the 
National Research Ethics Office of Brazil. 
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2.2.2 Clinical observations and collection of demographic data 
 
Upon recruitment, each participant’s parent/guardian was asked to 
complete a clinical and demographic questionnaire of 95 questions. This 
gathered information including demographic information such age, gender and 
date of birth. It also collected medical information including birth history, history 
of asthma, prematurity previous history of pneumonia or tuberculosis, allergies 
and vaccination history. Questions also covered social factors such as 
housing, number of siblings, fathers’ occupation, number of children sharing a 
room, mean family income and smoking in the household were also included.  
Clinical data such as heart rate, respiratory rate, temperature and 
oxygen saturation were also recorded on admission. The presence of 
identifiable clinical signs including cyanosis and chest in-drawing were noted. If 
the patient was admitted, clinical observations were recorded daily for the 
duration of hospital stay. 
Upon discharge each participant was assigned a discharge diagnosis 
by the attending physician who was not directly involved in the study. 
Diagnosis categories included; URTI, bronchiolitis, pneumonia, episodic viral 
wheeze/asthma and “other”. Diagnosis was classified as URTI if symptoms 
were confined to the upper respiratory tract, such as coryza, otitis media, 
sinusitis or tonsillitis with no obvious extension to the lower respiratory tract. 
Bronchiolitis was defined by lower respiratory infection signs such as wheeze 
or tachypnoea having been preceded by upper respiratory signs in children 
aged less than 18 months. Pneumonia was defined as the presence of 
tachypnoea, fever and crackles or decreased air entry on auscultation. For the 
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most part, pneumonia was diagnosed clinically and not radiographically 
although some patients did have a chest x-ray. A participant was classified as 
episodic viral wheeze if they had a history of discreet episodes of wheezing 
associated with an assumed viral infection. “Other” was any other diagnosis 
that was not suitably covered by other categories and included rarer 
presentations such as bronchiolitis obliterans. 
 
2.2.3 Sample Collection 
 
Once a child had been recruited, a Nasopharyngeal Aspirate (NPA) was 
collected in accordance with standardised protocol176. The process involved 
aspirating nasal secretions from both nostrils using a soft catheter with two 
lateral eyes and a port for finger tip suction control. The catheter was attached 
to a conical trap on a medium pressure vacuum and was advanced to a depth 
of 5-7cm and then withdrawn. Children were held by parents to reduce 
discomfort. Sample collection was undertaken by a single researcher during 
working hours (9am until 3pm, Monday until Friday) in accident and emergency 
(A&E) department. 
 
2.2.4  Sample preparation and storage 
 
Once collected all samples were processed within 3 hours of collection. 
Processing involved dilution of the sample within 3mls of sterile normal saline 
(0.9% NaCl in H2O) by aspiration through the catheter, so as to remove all 
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residual secretions. The solution collected was then centrifuged at 500g for 10 
minutes at 4°C. This allowed each sample to be divided into a supernatant and 
a cell pellet. They were separated and the cell pellet was re-suspended in a 
solution of 2-mercaptoethanol and RNA Lysis buffer (Qiagen, UK) in order to 
extract nucleic acid from each sample. This solution was then divided into two 
aliquots. All samples pellet and supernatant were then immediately placed at -
70°C and stored at this temperature until being transported to the Institute of 
Child Health at Alder Hey children’s hospital on dry ice. The timing from 
sample collection until freezing was less than four hours in all cases. 
 
2.2.5  Nucleic acid purification 
 
Upon arrival in Liverpool samples were stored at -70°C until nucleic acid 
purification was performed. The timing between NPA sample being collected 
and nucleic acid purification ranged from 2 months to 12 months.  Nucleic acid 
purification was performed with an automated kit, the QIAsymphony Virus/ 
Bacteria Mini Kit (Pathogen Complex 200 protocol) according to 
manufacturers’ instructions using the QIAsymphony automated machine 
(QIAGEN, Crawley, UK). For each patient 200µl of sample supernatant was 
utilised and eluted 60µl of both DNA and RNA which were co-extracted. Once 
extracted the purified nucleic acid was stored at -70°C until PCR was 
performed. 
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2.2.6  Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
After nucleic acid was extracted and purified RT-PCR was performed for 
18 different pathogens using six channels of the LightCycler 480 real time PCR 
machine (Roche Diagnostics, Burgess Hill, UK). The 18 pathogens were 
divided into 5 separate master mix preparation. The first included Flu A, Flu B, 
hMPV, RSV and novel pandemic H1N1 influenza (H1N1). The second 
included the CoV subtypes – HKU1, NL-63, 229E and OC43. The third 
included master mix primer probes for PiV types 1-4 and hRV. The fourth 
included primer probes for AdV, Chlamydophila pneumoniae and Mycoplasma 
pneumoniae. The final master mix included the primer probe set for Bocavirus. 
Master mixtures were made up on ice and nucleic acid was heated to 95°C 
before addition of master mix in order to allow denaturation. 5µl of sample was 
used in each sample for pathogens with RNA targets and 10µl for pathogens 
with DNA targets. 
 RT-PCR was then performed on the LightCycler 480 real time PCR 
machine. The PCR method, including primer probe genetic sequence is 
described by Hopkins et al (for complete primer sequences see Appendix A.1) 
177. Briefly, the reverse transcription process for Flu, H1N1, hMPV, RSV, CoV, 
PIV and hRV was carried out at 50°C for 20 minutes, denaturation at 95°C for 
2 minutes and then 50 amplification cycles of 95°C for 15 seconds, 58°C for 45 
seconds and 72°C for 1 second177. Each well contained 20µl of master mix and 
5µl of purified RNA. Reverse transcription for AdV, Mpp and Cpp was similar 
and differed by removing the 50°C hold step and the enzyme activation step at 
95°C was extended to five minutes. The contents of the wells were altered 
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slightly with 15µl of master mix and 10µl of sample. RT-PCR for other 
pathogens was performed using the Roche LC480 Probes Master kit (Roche 
Diagnostics, Burgess Hill, UK). Bocavirus differed in that it used the Qiagen 
Quantitect Probe PCR kit (Qiagen, Crawley, UK). The bacteriophage MS2 
replicase gene was present in each master mix, this acted as an internal 
control to ensure amplification of genetic material had occurred, it has 
previously been demonstrated that this internal control is suitable for viral 
respiratory pathogen identification178. 
 
2.2.7  PCR Analysis 
 
 For each pathogen a positive control and negative control was 
contained on each plate. Individual pathogens on the same plate were 
analysed by use of the multi-channel analysis of different wavelengths. The 
LightCycler 480 machine provided analysed results with amplification plots. 
These amplification plots were then checked by two researchers to confirm 
positive and negative samples in any amplification plots that were unclear, this 
was done by comparing each sample individually to the control positive and 
negative samples to decide the cycle and magnitude of amplification of a 
sample. 
 
2.2.8  Statistical analysis 
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All results were then added to the statistics package SPSS 18.0.0 (SPSS Inc, 
Chicago). Frequencies of pathogen prevalence were calculated using SPSS 
and graphs produced with Microsoft Excel 2007 (Microsoft Inc). Differences in 
prevalence, admission rates and presence of co-infection were calculated 
using the Fisher Exact test for smaller numbers and chi squared for larger 
samples. Variation between groups was assessed with the Kruskall-Wallis test. 
Significance in all cases was considered as p<0.05.  
 For analysis purposes pathogens were grouped. PiV types 1 – 4 were 
considered as “Parainfluenza”; “Coronavirus” included the subtypes CoV 
OC43, CoV HKU1, CoV229E and CoV NL63. Influenza A and B were 
considered as “flu” for comparison between the two years, in the second year 
of the H1N1 pandemic the novel H1N1 was also considered separately. 
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2.3 Results 
 
2.3.1  Recruitment and patient demographics 
 
Over the two year study period 630 children presented with ARI and 
were recruited to the study. The cohort contained more males than females 
(n=345, 55%). The median age of children presenting with ARI was 7 months 
(range 0-57 months) with 530 (84%) children below 18 months and 452 (72%) 
children being less than 12 months. Hospital admission was required in 339 
(54%) of children due to severity of their ARI, with the median length of stay for 
those requiring admission being 4 days (range 0-38 days). A member of the 
household smoked in 263 (42%) of children. Family mean income was 
recorded in 65% of patients and was found to be US$ 276; this was 
significantly lower than the Brazilian mean (US$ 450). 
Recruitment was higher in the first year (n=407, 65%) compared to the 
second year (n=223, 35%) (Table 2.2). In the second year the gender 
distribution was more equal and the age of children presenting with ARI was 
lower (median 7 months vs. median 6 months p=0.005). Otherwise, all other 
demographics were similar between the two years. 
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Table 2.2: Demographics of children recruited to study. (*=significant 
difference, p<0.05) 
 Entire study 
(April 2008-
March 2010) 
Year 1 
(April 2008-
March 2009) 
Year 2 
(April 2009-
March 2010) 
N 630 408 222 
Gender 55% Male 58% Male 50%* 
Median age 
(range) 
7 months (0-
57) 
8 months (0-
57) 
6 months (0-
45) 
Birth weight 
<2500g 
15% 14% 16% 
Breast Fed 92% 92% 92% 
Co-Morbidities 5% 5% 6% 
Smokers at 
Home 
42% 43% 40% 
Hospital 
Admissions 
54% 52% 57% 
Co-Infection 43% 40% 50%* 
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2.3.2  Clinical information 
 
The most common discharge diagnosis was bronchiolitis (n=335, 52%) 
followed by pneumonia (n=189, 30%) and episodic viral wheeze/asthma 
(n=59, 9%) with the least common diagnoses being upper respiratory tract 
infection (n=35, 5.6%) and “other” (n=11, 2%) (Figure 2.1). “Other” diagnoses 
included conditions such as bronchiolitis obliterans and whooping cough. A 
total of 32 (5%) children had a medical co-morbidity e.g. non-cyanotic heart 
disease or neurological disability.  Breastfeeding was common with 580 (89%) 
of parents reporting the child was breastfed or weaning.   
 Clinically 87 (13%) of children had evidence of hypoxia (peripheral 
oxygen saturation <90%) and 43 children (7%) required oxygen 
supplementation during their hospital visit. Hypoxia was clinically evident in a 
small number of children, with 48 (7%) having chest in-drawing documented on 
admission. A fever (defined as temperature >38°C) was present in 105 
(16.2%) of children.  There were 3 children (0.5%) within the study who died 
during their admission to hospital for ARI. 
 In the second year the diagnosis of pneumonia was more common than 
in the first (27% vs. 35% p=0.02) and the diagnosis of EVW / asthma was 
made less frequently (13% vs. 2% p<0.01). There were no significant 
differences in the frequency of children presenting with URTI (6% vs. 6%), 
bronchiolitis (53% vs. 56%) or “other” (2% vs. 1%).  
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Figure 2.1: Frequency of clinical diagnoses of all children recruited to study.  
(n=630, URTI = Upper Respiratory Tract Infection. Episodic Wheeze = 
Episodic Viral Wheeze / Asthma) 
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2.3.3  Pathogen detection  
 
All samples were successfully tested for 18 different pathogens by RT-PCR.  
At least one pathogen was detected in 87.6% of samples with detection rates 
being higher in the second year (91.5% PCR positive) compared to the first 
year (85.5% PCR positive).  
 Overall the most commonly detected pathogens over the two year study 
period were RSV, AdV, hBoV and hRV (33.2%, 28.7%, 24.4% and 18.7% 
respectively)  (Figure 2.2). The pathogens hMPV, PiV, Mpp and Flu were 
detected in smaller amounts (9.5%, 9.5%, 8.4% and 7.1%) with the least 
prevalent pathogens CoV and Cpp being detected infrequently (4.4% and 
3.1% respectively). 
 By dividing the study into two twelve month periods (April 1st 2008 – 
March 31th 2009 and April 1st 2009 – March 31st 2010) significant differences in 
the annual prevalence of some pathogens were observed. A significant 
decrease in the prevalence of RSV was detected in the second year (37.3% 
vs. 22.9% x2 = 13.82 p=<0.001). Other pathogens showed significant 
increases in prevalence with the most significant increase being that of 
influenza (2.7% vs. 15.2% x2= 34.17 p=<0.001) (see section 2.3.6). Other 
pathogens that demonstrated increased prevalence in the second year 
included hBoV (18.7% vs. 35.0% x2=20.74 p=<0.00001), AdV (24.8% vs. 
35.9% x2=8.60 p=0.003) and CoV (3.2% vs. 6.7% x2=4.23 p=0.04). 
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Figure 2.2: Percentage prevalence of pathogens in entire study 
 (April 2008-March 2010, light blue), 1st year of study (April 2008-March 2009, 
red) and 2nd year of Study (April 2009-March 2010, green) (* = p<0.05 for 
differences in frequency of pathogens between years, ** = p <0.01) NB sum of 
prevalence is >100% due to frequency of co-detection 
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2.3.4  Co-detection 
 
Co-detection / co-infection is when more than one pathogen being 
detected on PCR from one sample. High levels of co-detection of multiple 
pathogens were found.  More than one pathogen was detected in 272 (43.2%) 
samples. This was higher in the second year compared to the first year (50% 
and 40% respectively p=0.009). The highest number of pathogens 
simultaneously detected was five and this occurred on three occasions (0.5%) 
(Figure 2.3). Co-infection was not associated with increased severity of ARI, 
with there being no association between co-infection and hospital admission in 
our group (x2=0.23 p=0.63). 
 In patients samples where more than one pathogen was detected (“co-
infections”) the most common pathogens detected were AdV, hBoV, RSV and 
hRV (54.4%, 48.1%, 37% and 29.9% respectively of total co-infection 
frequency  (Figure 2.4 and Figure 2.5). When observing overall detection of a 
pathogen as a proportion of samples which were detected as co-infections, the 
pathogens with the highest proportion of positive results being present in co-
infections were Cpp (87.5% of Cpp detected as a co-infection), hBoV (84.4%), 
AdV (81.2%) and Mpp (79.2%). In contrast, the pathogens that were least 
common to present as co-infections were RSV (59.3% of RSV detected as co-
infection), hRV (59.3%) and PiV (63.3%). 
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Figure 2.3: Prevalence of co-detection as a percentage of all samples. 
 (PCR –ve = no pathogens detected on PCR) 
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Figure 2.4: Prevalence of pathogens presenting with co-infection as 
percentage of all co-infections. 
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Figure 2.5: Frequency of pathogens presenting as mono-infection and co-
infection shown as proportion of total pathogens detected. 
 (Red = mono-infection Blue = co-infection Total size of bar = frequency of 
pathogen detected) 
 
 
 
 
 77 
2.3.5  Temporal relationships 
 
This study collected clinical samples over two years and so analysis of 
temporal patterns was possible (Figure 2.6). The rainy season in Recife 
occurs between April and July. Seasonality was demonstrated most clearly for 
RSV with a seasonal increase being apparent between March and August of 
both years. There was also variation in the monthly prevalence of influenza 
which will be discussed in the following section in more detail. Some 
pathogens seem to be endemic such as AdV and hBoV. 
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Figure 2.6: Temporal relationships of pathogens detected divided into monthly 
percent prevalence each month  
(arrow represents emergence of pandemic H1N1 in Mexico) 
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2.3.6  H1N1 Pandemic 
 
Of the 45 samples that were positive for Flu on RT-PCR, 27 were of the 
novel H1N1 influenza subtype (4.3% overall) with the first case being detected 
on the 20th August 2009. The demographics of both non-H1N1 influenza and 
H1N1 influenza was comparable to the demographics of the study population 
with regards gender, age, birth weight, breast feeding and parents smoking at 
home (Table 2.2). Significant differences were seen however with children in 
who H1N1 was detected being more likely to require hospital admission 
compared to non-flu ARI (78% vs. 53% x2 = 6.48 p=0.01) and compared to 
non-H1N1 flu ARI (78% vs. 44% x2=5.24 p=0.02).  
Rates of co-infection were also significantly higher in the H1N1 group 
compared to non-flu ARI (78% vs. 41% x2=14.4 p<0.001) and was increased 
compared to non-H1N1 flu but not to the level of significance (78% vs. 56% 
p=0.12). The most common pathogens detected simultaneously with H1N1 
were AdV and hBoV, both being detected in 40.7% of H1N1 positive samples 
(Figure 2.5). There was a single child with five pathogens detected 
simultaneously and these included AdV, H1N1, PiV, CoV and hBoV.  
With regards clinical presentations all children found to have H1N1 on 
RT-PCR presented with lower respiratory manifestations of ARI (48% 
bronchiolitis, 52% pneumonia) (Table 2.2). 
The temporal relationship of H1N1 was clearly defined throughout our 
study period (Figure 2.8). This shows the emergence of novel H1N1 influenza 
compared to non-H1N1 influenza. There was no month in which the two were 
detected simultaneously and H1N1 appears to present outside of the influenza 
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season, with cases of non-H1N1 flu being detected between March and July of 
both years. The monthly prevalence of H1N1 is also higher than non-H1N1 flu. 
Prior to the H1N1 pandemic, flu represented an infrequent pathogen detected 
in few cases of ARI with the highest prevalence being 13%. After the 
emergence of H1N1 the prevalence increased with a peak prevalence of 30% 
in December 2009. In the six-month period of October 2009 until March 2010 
H1N1 was detected in 20% of samples collected. 
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Table 2.3: Demographics of children presenting with novel H1N1 influenza 
compared to Non-H1N1 influenza and Non-influenza ARI. 
 (* = p<0.05 comparing H1N1 influenza positive ARI to non-H1N1 ARI)  
 
 2008-2010 (n=630) 
Non-Flu Non-H1N1 Flu H1N1 Flu 
N 585 18 27 
Gender Male 56% Male 39% Male 48% 
Median age 7 months (1-57) 8.5 months (0-
31) 
8 months (range 
0-44) 
Birth Weight 
<2500g 
14% 22% 15% 
Breast Fed 92% 83% 100% 
Co-Morbidities 5% 0% 7% 
Smokers at 
home 
41% 44% 48% 
Hospital 
admission 
53% 44% 78%* 
Co-infection 41% 56% 78%* 
Clinical 
diagnosis: 
   
URTI 6% 11% 0% 
Bronchiolitis 54% 50% 48% 
Pneumonia 29% 28% 52%* 
EVW 10% 11% 0% 
Other 2% 0% 0% 
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Figure 2.7: Percentage prevalence of pathogens detected as co-infections with 
novel H1N1 influenza. 
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Figure 2.8: Monthly percentage prevalence of non-H1N1 influenza (blue) and 
novel H1N1 influenza (red) over the 24 month study period. 
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2.4 Discussion 
 
2.4.1  Overview 
 
This findings of this investigation are divided into two sections; the first 
analysing the pathogens present in NPA of recruited children, the second 
assessing the role of the novel H1N1 swine influenza pathogen in this age 
group. 
 
2.4.2  Pathogen Detection 
 
Over the two-year period, we clearly described the pathogens involved 
in ARI in pre-school children. At least one pathogen was identified in 87.6% of 
patients. This detection rate was generally high compared to the literature, with 
many similar studies finding pathogens in only 47-60% of samples 47 115 169. 
However, similar levels of detection have been reported in a number of studies 
with rates of 88-90%,173 174. A possible reason for our high levels of detection 
may be the wide range of pathogens that we tested for. There was no 
difference in methodology or handling of samples in the two years. 
 We recorded the clinical diagnoses, with the majority of ARI being LRTI. 
The most common manifestations were bronchiolitis (53%) and pneumonia 
(30%) (Figure 1.1). EVW and URTI were less common (9% and 6% 
respectively) and 2% of children were classified as “other”. The most common 
diagnoses being bronchiolitis is not surprising due to the low median age of 
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our study (7 months). Bronchiolitis is common in this age group, 2% of children 
under two years are hospitalised with the condition31. 
 The most commonly detected pathogens were RSV, AdV, hBoV and 
hRV (33%, 29%, 25% and 19% respectively). RSV has previously been 
described as one of the most common pathogens detected in ARI in young 
children. Berkely et al found RSV to be present in 34% of PCR positive 
samples in children presenting with LRTI47. This probably reflects the young 
age, bronchiolitis being the most common clinical diagnosis in children 
recruited (52%). We also showed the seasonal nature of RSV (Figure 2.6), a 
feature which is well documented in the developed world but less so in South 
America. The seasonal nature correlates closely with Recife’s rainy season 
(April-July). RSV prevalence was significantly lower in the second year of the 
study. This is due to the second years “RSV season” spanning the artificial cut-
off between the first and second year of the study. 
 Another interesting finding was the high prevalence of Adv in our cohort, 
previous reports on AdV prevalence in childhood ARI has varied. Both Sung et 
al and Do et al found AdV present in 5% of samples from children <5 years 
and <15 years respectively169 172. However higher levels of AdV have been 
reported, 37% of ARI in children <5 years in Jordan and 20% in children <3 
years in Alaska174 175. Our findings support AdV being a highly prevalent 
pathogen in paediatric ARI, found in 29% of samples. There was also no clear 
seasonal variation (Figure 2.6). Reasons for disparity in the literature are 
unknown. The median age studies finding low levels of AdV is higher, with 
both Sung et al and Do et al’s median age being 24 months, compared to 
studies detecting high levels with Kaplans et al’s median age being 5 months 
 86 
and Singleton et al focusing on children <3 years with 64% <12 months169 172 
174 175. Our cohort’s median age was 7 months and median age in AdV positive 
children was significantly higher than AdV negative ARI (6 vs. 8 months 
p<0.01). A second possibility for high prevalence is cramped living conditions, 
the mean number of children sharing a room was 3.1 in the 407(65%) children 
where information was collected. Historically AdV infection is associated with 
living in high density conditions84. Also it is possible AdV infection may persist 
in the airway, some studies have shown the same strain of AdV can be 
present for over 200 days in the same patient93. 
 High prevalence of hBoV is also of interest as there has been no 
consensus on the exact prevalence of hBoV in childhood ARI. Previous 
studies have suggested prevalence of 3-19%106. Our study reports a higher 
level of hBoV. It has been suggested transmission of hBoV may be by faeco-
oral route, being present in 9% of children with gastroenteritis106. A possible 
explanation for our high prevalence is the majority of our cohort lived in favela 
or slum housing in Recife where faeco-oral transmission of pathogens such as 
hBoV may occur more frequently. Data collected for our cohort suggested the 
mean family income (US$276) was significantly lower than the Brazilian mean 
(US$450)179. 
 Less prevalent pathogens were found in frequencies in keeping with the 
literature on paediatric ARI. PIV was found in 10% of our cohort which is 
similar to other reported findings of 7-13% of paediatric ARI47 115 172. CoV was 
detected in 4% of samples, similar to reported literature of 1-10%47 173 180. In 
the first year we found high levels of Mpp with a demonstrable peak in 
infections and an association with pneumonia presentations167. The 
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prevalence of Mpp was lower in the second year (6%) (Figure 2.2) and there 
was no observable seasonal peak (Figure 2.6) 15% of Mpp infections did 
present with the diagnosis of pneumonia.   
 Co-infection was common in our study (43%) of children, other studies 
have reported co-infection in 14-22% of ARI presentations115 172 175. The most 
common pathogens present in co-infection were AdV, hBoV and RSV. Wang 
et al described co-infection rates of 14% with the most common pathogens 
being hBoV, RSV, hRV and AdV115. Our finding of AdV being the most 
common pathogen involved in co-detection is most probably related to its high 
prevalence, which was discussed previously.  Similarly, RSV being a common 
pathogen in co-infection is probably due to its high prevalence. hBoV has 
previously been reported to be associated with co-infection, presenting as a 
multiple pathogen in 50-70% of cases106. Our study found this to be true, with 
84% of hBoV positive samples being co-infections.  
Overall our results found no correlation with co-infection and 
hospitalisation (p=0.63). Other studies have found the converse to be true, 
Semple et al described hMPV and RSV co-infection being associated with 
severe bronchiolitis181. Some pathogens are documented to cause increased 
severity when simultaneously present e.g. influenza and S pneumoniae182. Our 
results do not seem to agree with this but a possible explanation is the large 
range of pathogens we tested for compared to other studies. Also hBoV is not 
tested for frequently in similar studies, and was a common cause of co-
infection in our cohort. It is plausible that certain combinations increase 
severity in our cohort but are not apparent due to the large number of 
pathogens we tested for.  
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Finally there was significant difference in co-infection between the two 
years of the study. The most likely explanation for this is the increased 
prevalence of AdV and hBoV in the second year with both pathogens 
presenting commonly as co-infections. 
 
2.4.3  H1N1 Pandemic 
 
The timing of our study coincided with the emergence of the H1N1 
influenza pandemic. When comparing two years of the study, the pathogen 
with the most significant change in prevalence was influenza, going from the 
ninth to the fourth most prevalent pathogen. Most (79%) of these cases in the 
second year were due to H1N1. Demographic data for individuals with H1N1 
were comparable to those with non-H1N1 ARI. We found that the proportion of 
children with H1N1 who had co-morbidities was not significantly different to 
non-H1N1 flu and non-Flu ARI. Other studies documenting the pandemic 
showed children with cardiovascular or respiratory co-morbidities to be at 
higher risk of severe H1N1 ARI126. We did not find this in our cohort, possibly 
due to type 2 statistical error as many of the studies finding this feature were 
studying larger populations and the percentage of co-morbidities was higher in 
the H1N1 group although not significant. Baker et al used data from South 
Africa, South America and Australia, over 21,000 reported cases, and 
highlighted was the presence of co-morbidities183.  
 In our study median age of children found to have H1N1 was also 8 
months, and 63% were below 1 year old. The Flu-CIN cohort reviewed 631 
cases of H1N1 and demonstrated 16% of all cases were under 5 years of age, 
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7% under 1 year129. The finding that young children are at high risk is well 
documented in the setting of H1N1126. Our findings would be in agreement. We 
found no significant difference between age of presentation in the H1N1 
positive children compared to non-H1N1, most likely because young age is a 
well recognised risk factor of ARI in general.   
 All children in our cohort who suffered H1N1 infection had lower 
respiratory infection (48% bronchiolitis and 52% pneumonia). H1N1 was 
significantly more likely to present with pneumonia compared to non-H1N1 
ARI. However, the clinical presentation of H1N1 varied from mild febrile illness 
to diffuse viral pneumonitis126. In our study, a significant proportion of children 
presented with pneumonia, showing the severity of this novel pathogen. The 
Flu-CIN group found that 35% of children with H1N1 presented with 
pneumonia129. Other groups have described pneumonia frequency in H1N1 
positive patients of all ages to range from 18-66%184. We demonstrate 
pneumonia is a common manifestation of H1N1 in a child which implicates it as 
an important pathogen in severe childhood ARI. 
 Infection with H1N1 was also associated with hospital admission 
compared to non-H1N1 ARI. Literature suggests the majority of infections are 
mild and do not require hospitalisation116. Bryant et al analysed the prevalence 
of H1N1 in <16 year olds and found that in 119 confirmed cases 5 required 
hospitalisation (4%)185. Within our cohort the majority of those presenting with 
H1N1 (78%), and indeed all causes of ARI (overall 54%) required hospital 
admission. This finding is larger than Bryant et al and could potentially be the 
young age of our cohort and the large proportion presenting with pneumonia.  
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 Co-infections were significantly higher in the H1N1 population compared 
to the non-H1N1 population in our study. The most common pathogens 
detected simultaneously were AdV and hBoV. In comparison to overall co-
infection RSV was not a common pathogen detected with H1N1, due to the 
H1N1 pandemic being separate to the RSV season (Figure 2.6). Co-infection 
was not associated with increased likelihood of hospital admission. We are 
unable to comment upon co-infection with bacterial pathogens, with much of 
the co-infection literature on H1N1 focusing on this topic. Koon et al 
demonstrated high levels of co-infection in the H1N1 pandemic with S. aureus 
and S. pneumoniae being the most commonly co-detected pathogens 186. Our 
findings would be in agreement that co-detection is a common feature of novel 
H1N1 infection.  
 There was a striking difference in influenza prevalence between the two 
study years. When further analysed 79% of influenza infections in the second 
year were of H1N1 subtype. There is little literature on the change in 
prevalence with the emergence of H1N1, as many studies began collection of 
H1N1 samples after the pandemic was declared. In Brazil it was reported 
H1N1 was widespread in July and peak incidence was in August187. We report 
these features to be later in our population with initial appearance in August 
and peak prevalence in November. We also found no influenza-B (flu-B) 
infections were detected. This is reasonable as the prevalence of Flu-B is 
documented to be lower than flu-A, especially in seasonal epidemics. There 
have been reports of flu-B increasing in prevalence after the H1N1 
pandemic188. Our findings were unable to show this trend, although our study 
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only continued for one month after the initial wave and so this change may not 
yet have become apparent. 
 
2.4.4  Limitations 
 
 Our study was able to achieve its original aims and describe the viral 
pathogens detected in the airways of children presenting with ARI to hospital in 
Brazil, there were a number of possible limitations which must be 
acknowledged. The techniques we used were not able to quantify the amount 
of pathogen that was present in the airways with results being qualitative in 
nature. This was due to the technique of NPA not guaranteeing to collect the 
same amount of aspirate fluid at a specific concentration. It would have been 
of interest to know quantity of pathogens in order to decide whether an acute 
infection was occurring or the participant had a low level of pathogen present. 
The nature of PCR technique means that pathogens that may not be involved 
in active ARI but are present within the airway and this feature must be 
acknowledged, especially in multiple infections. A possible means of 
accounting for this would have been the use of a control group but very few 
studies in the literature recruit such a group. One of the largest studies that 
achieved this to date was by Singleton et al in Alaska, their findings suggested 
that the involvement of some pathogens such as hRV, CoV and AdV may not 
be associated with ARI compared to controls174.  
 A second limitation is that we did not test for a wide variety of bacterial 
pathogens. Although we aimed to assess the viral and atypical bacterial 
causes of ARI and tested for more pathogens than many studies in the 
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literature, we did not investigate bacterial causes of ARI, such as 
Pneumococcus and Hib. It would be reasonable to assume that many patients 
recruited would have been infected with some of these pathogens. It has been 
previously shown that C-Reactive protein in the airway sample is associated 
with bacterial infection, however it was not in the protocol of this study to test 
for this189. It also is of further interest as streptococcus has been shown to 
interact with influenza infection and an association with respiratory viruses and 
invasive pneumococcal disease has been previously shown117. 
RT-PCR is a highly sensitive and specific technique, NPA is also shown 
to have high diagnostic yield176. NPA has been shown to be superior to 
sampling with nasal swab, although some studies have performed both with 
literature suggesting this may produce higher sensitivity for infections190. A 
possible limitation in our sampling method is that we only assessed the viruses 
and atypical bacteria within the upper airways and these results may not be 
representative of the lower airways. Despite these limitations the technique is 
relatively non-invasive (compared to sampling the lower airways) and can be 
used in a large number of participants. 
 Classifications of clinical diagnosis in this study may have varied with 
different physicians. It is feasible that making definitive diagnoses may have 
been difficult, especially when differentiating bronchiolitis and pneumonia in a 
young infant. It is not clear how this possible limitation could have been 
avoided as further diagnostic tools were not available in the setting of this 
hospital, but it is acknowledged that this may have occurred. 
 One final possible limitation is the difference in recruitment between the 
two years in the study. The reason for this was due to one researcher taking 
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NPA samples and her availability being less in the second year. There were 
some differences in demographics with median age being significantly lower in 
the second year. The difference in median age was one month however with 
both years having a large proportion of children under the age of 1 year so the 
difference may be minimal. Details on overall hospital presentations is not 
collected by the hospital so we cannot comment if the proportion of ARI 
presentations recruited was comparable between the two years. 
 
2.4.5  Further Work 
 
Our work has been successful in its original aims of analysing viral and 
atypical bacterial pathogens present in paediatric ARI. It has also raised a 
number of ideas for further work. Some of the pathogens we found in high 
levels are in agreement with current literature such as RSV. However others 
have been reported in higher levels than previously documented. It would be of 
interest to assess more fully the reasons for high levels of AdV and hBoV. If 
the reason for this is the slum conditions and high population density in our 
group this could be achieved by comparing with a different population in a 
more developed setting.  
 Co-infection was a common finding in our study and due to the range of 
pathogens tested for and variety of combinations we were unable to analyse 
this fully. Further analysis of this could be achieved by comparison to a control 
group with no respiratory symptoms. Few studies have made this comparison 
although the few that are able to have raised interesting findings on the role of 
pathogens, with some established pathogens being suggested to have no 
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association with ARI174. Our study found no association with co-infection and 
increased severity of ARI although this has been found in previous work, it 
would also be of interest to analyse this in children.  
 Finally our study was able to demonstrate the emergence of the novel 
pathogen H1N1 swine influenza; the clinical differences that were shown show 
the importance of analysing new pathogens. Possible further work could be to 
analyse how this pathogen presents in the next flu seasons to assess the 
populations change in response over time. 
 
2.4.6  Conclusions 
 
The first aim of this study was to assess the causative pathogens of ARI 
in this population where viral diagnostics are not traditionally available. In this 
we found a variety of viral pathogens to be detected in the airways of children 
with ARI. Of the most prevalent pathogens some have been highly studied and 
were in keeping with the literature, such as RSV although we demonstrated 
the epidemic nature of this pathogen in a temperate climate where it is 
relatively less proven. However we identified a number of pathogens 
presenting at levels that differed from previous literature. We found AdV and 
hBoV to be common pathogens in our study which could potentially be due to 
the young age of our patients or the social conditions from which we recruited. 
Co-infection was a common occurrence in our study and highlights the 
complexity of pathogen interaction within paediatric ARI suggesting possible 
areas for further work.  Overall we have managed to give both an overview of 
the pathogens involved in ARI, reporting a high positive rate of 88%, as well as 
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demonstrating the seasonal nature of specific pathogens. We highlight the 
severity of ARI in the paediatric population with the majority presenting as 
lower respiratory infections and hospital admission being required in 54% of 
patients who presented. 
 The second aim was to assess the impact of H1N1 swine influenza. We 
have shown that in one of the populations most at risk of the disease that 
H1N1 infection presented predominantly as LRTIs and often with more than 
one infection compared to non-H1N1 ARI. H1N1 infections appeared to be 
associated with more severe ARI with more children requiring hospitalisation 
who were infected. Furthermore, the pandemic did not appear to significantly 
affect the prevalence of other common circulating respiratory viral and atypical 
bacterial pathogens. Of note, the H1N1 pandemic in this population was 
dwarfed by the annual RSV season epidemic. 
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3 An investigation into the prevalence of hRV-C 
in paediatric acute respiratory infection 
 
3.1 Introduction 
 
3.1.1  Chapter overview 
 
 The third chapter of this thesis assesses the prevalence of human 
Rhinovirus (hRV), including hRV-C, in our preschool cohort with ARI from 
Recife, Brazil. In hRV-positive samples, genetic amplification techniques were 
used to type and categorise hRV groups – A, B or C.  Demographic and 
clinical features of all hRV samples were recorded to characterise any features 
specific to these groups.  
 
3.1.2  Introduction 
 
 Human Rhinovirus (hRV), first described in the 1960s and has 
traditionally been implicated as the most common causative pathogen of 
URTIs and the common cold (see section 1.3.3)84. A cure for the common cold 
was a much publicised goal in the 1960s due to its frequent nature and large 
economic burden. This led to much research focusing on hRV and showed its 
replication cycle to occur at temperatures between 33°C and 35°C. This finding 
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led to the belief that hRV could only be present in the upper respiratory tract 
and would not be able to infect the lower airways97. Research into hRV 
continued and by 1987, 100 serotypes of hRV had been characterised by use 
of viral culture and neutralising antibody studies95. These serotypes consisted 
of two groups based on partial genetic sequences and responses to certain 
antiviral medications – hRV-A and hRV-B97. The hRV serotypes were also 
divided into “major” and “minor” groups depending on the two main receptors 
to which the virus would bind; intracellular adhesion molecule-1 (ICAM-1) and 
low-density-lipoprotein receptor respectively97. The discovery of appropriate 
receptors led to production of targeted antiviral medications but due to 
excessive cost and low efficacy these were never widely accepted. After this, 
interest in hRV dwindled and it was widely regarded as a minor respiratory 
pathogen with effects limited to the common cold. 
 In recent years the impact of hRV has been re-evaluated. It has been 
shown that hRV infection plays an important role in lower respiratory infections. 
Originally it was hypothesised that detection was contamination from the upper 
airway. However, analysis of secretions from tracheostomies were able to 
demonstrate definitively that hRV can be found in the lower airway without 
contamination191. The increasing availability of advanced viral diagnostic 
techniques such as RT-PCR also allowed increased sensitivity compare to 
previous viral culture techniques. These studies highlighted that hRV was 
commonly detected in lower respiratory presentations of ARI,  with many cases 
in children who were negative for other pathogens192.  
hRV has also been shown to be one of the most common pathogens 
detected in asthma exacerbations, found in up to 85% of samples97. Young 
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children infected with hRV have also shown to be at increased risk of episodic 
viral wheeze in later life with some studies reporting this risk to be even greater 
than RSV infection193. With these newly discovered features of hRV, it is now 
accepted that it is an important pathogen in paediatric ARI. 
 In 2005/2006 molecular diagnostic techniques found that some strains 
of hRV were significantly dissimilar from the previous classification system. 
Groups in Australia and New York all reported that a new hRV group had been 
detected in paediatric respiratory disease194 195. Despite different strains 
demonstrating significant variation specific genetic regions have been 
identified for characterisation of hRV strain, namely the Viral Protein (VP) 
regions (VP2, VP4) and the traditionally used 5’ NCR region95.  These new 
strains constituted a new group classified as “Rhinovirus-C” (hRV-C) 95. The 
discovery further highlighted the hRV family of viruses as an evolving and 
changing set of viruses with many undiscovered strains.  
Further studies have shown that hRV-C is a common cause of ARI. In 
some studies, hRV-C has been shown to be more prevalent than hRV-A 
accounting for 64% - 81% of hRV detected in ARI or asthma exacerbations100 
196 197. Some studies have also reported clinical differences between hRV-C 
and other hRV groups. One study showed that it was associated with more 
severe asthma exacerbations than other groups, although other studies have 
showed no such difference198 199. 
 Overall the novel group hRV-C represents a newly identified family of 
respiratory pathogens which have commonly been found in paediatric ARI and 
especially asthma presentations. Recent advances in molecular diagnostics 
have given the opportunity to analyse these strains in detail. Reports of 
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increased severity and differing clinical presentations raise concerns that this 
subgroup may represent an important pathogen that causes burden in 
childhood respiratory disease. This highlights the need to assess the clinical 
impact of this novel group of hRV in paediatric ARI. 
 
3.1.3  Aims of this study 
 
 This study follows on from the previous chapter detailing pathogens 
found to be present in paediatric patients presenting with ARI from Brazil. As 
part of that larger study we will further analyse the samples that were found to 
have hRV infection present. As stated in Section 1.10 the aims of this 
investigation is to describe the role of the novel hRV group, hRV-C, in 
paediatric ARI.  
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3.2 Methods 
 
hRV strain analysis was performed by members of Professor Peter le 
Souef’s group in Perth, Western Australia. 
 
3.2.1 Reverse Transcription 
 
RNA samples from children in which hRV had been identified by RT-PCR 
were reverse transcribed to cDNA so that they could be transported easily to 
Australia. Reagents used included random primers, AMV-RT, RNAse inhibitor 
and dNTPs (all Promega, USA) which were used to make a master mix. 
Master mix 30µl was then pipetted into 20µl of each sample, the entire process 
being performed on ice. Once prepared, sample and master mix were reverse 
transcribed using a thermocycler TC-512 machine (Techne, UK) with 
conditions of 35 minutes at 42°C, 20 minutes at 50°C and finally 5 minutes at 
85°C. All sample cDNA was then stored at -30°C prior to transportation to 
Perth, Australia for further analysis. This process was in keeping with that 
described previously in the literature200. 
 
3.2.2 Transportation  
 
All samples were packaged in dry ice and sealed; they arrived at their 
destination within 36 hours when they were returned to storage at -30°C. A 
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Material Transfer Agreement (MTA) from Liverpool, UK to Perth, Australia was 
obtained prior to dispatch. 
 
3.2.3  Analysis of Rhinovirus Subtype 
 
 The method used by the Perth group to analyse hRV strain and group 
has been published100 and is based on a technique pioneered in Professor Jim 
Gern’s laboratory in Wisconsin, USA200 201. The method uses a molecular 
assay that targets the 5’ Non-Coded Region (NCR) of the HRV genome to 
identify strain, a sequence of 260 base pairs which is the most conserved 
genomic region between different hRV strains200. Briefly, cDNA was amplified 
using two-step amplification using specifically designed. PCR primers and 
cycling conditions described previously200. PCR products were sequenced by 
the Australian Genome Research Facility. The amplified sequences were then 
compared to a database of known strains, including both the original 101 hRV 
strains and the newly identified strains using phylogenetic tree analysis 
software (ClustalX) to determine strain. The hRV group was assigned based 
on the 420 bp VP4/VP2 sequence which was also amplified in these strains. 
Due to the close genetic similarity between hRVs and Enteroviruses (EnV) 
sequences were also checked with known EnV sequences. 
 
3.2.4 Statistical analysis: 
 
 102 
 Once each sample was assigned a strain and group, statistical analysis 
was performed on SPSS v18.0.0 (SPSS Inc, Chicago). Frequencies of hRV 
pathogens and prevalence’s of subgroups were calculated on SPSS and 
graphs produced on Microsoft Excel (2007, Microsoft Inc). Differences in 
hospital admissions, prevalence between years, clinical presentations and co-
infection were calculated with chi-squared test. Variation between groups was 
assessed with Kruskall-Wallis Test. Difference in age was calculated with 
Mann-Whitney U test. A p-value <0.05 was considered significant.   
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3.3 Results 
 
3.3.1 Patient Recruitment and Demographics 
 
 In total hRV was detected by RT-PCR in samples from 118 (18.7%) 
children from the Recife cohort making it the fourth most prevalent pathogen in 
the 630 children recruited. Demographics of children were not significantly 
different between the hRV positive group and those children presenting with 
non-hRV ARI (Table 3.1). Of the 118 hRV positive children 65 (55%) were 
male. The median age of these children was 6 months (range 0-48 months), 
with 113 (96%) being under 18 months and 89 (75%) under 12 months of age. 
Twenty two children (19%) had a history of low birth weight and 47 (40%) had 
a member of the household who smoked. Co-morbidities were less common in 
the hRV group compared to non-hRV ARI (3% vs. 6%) but this difference was 
not significant. The severity of ARI in 67 patients (57%) necessitated 
admission to hospital.  
 The most common diagnosis in children with hRV infection was 
bronchiolitis, which was diagnosed in 68 (58%) of patients. Pneumonia was 
diagnosed in 30 (25%) and episodic viral wheeze (EVW) / asthma and URTI 
were diagnosed in 10 (9%) and 6 (5%) of children respectively. 
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Table 3.1: Patient demographics and clinical diagnoses comparing those with 
hRV positive ARI and hRV negative ARI. 
 (EVW = episodic viral wheeze / asthma. URTI = upper respiratory tract 
infection. All presented as n (%). *= significant difference p < 0.05) 
 ALL HRV NON-HRV ARI  
N 118 512 
GENDER 64(54%) MALE 281(55%) 
MALE 
MEDIAN AGE 
(RANGE) 
6 MONTHS (0-
48) 
7 MONTHS (0-
57) 
BIRTH WEIGHT 
<2500G 
22(19%) 70 (14%) 
BREAST FED 107(91%) 473 (92%) 
CO-MORBIDITIES 4(3%) 28 (6%) 
SMOKERS AT 
HOME 
47(40%) 216 (42%) 
HOSPITAL 
ADMISSION 
67(57%) 272 (53%) 
CO-INFECTION 70(59%)* 200 (39%)* 
CLINICAL 
DIAGNOSIS: 
  
URTI 6(5%) 29 (6%) 
BRONCHIOLITIS 68(58%) 267 (52%) 
PNEUMONIA 30(25%) 159 (31%) 
EVW 10(9%) 49 (10%) 
OTHER 4(3%) 7 (1%) 
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Figure 3.1: Percentage prevalence of pathogens detected in co-infections with 
hRV 
 (AdV = Adenovirus, hBoV = human bocavirus, RSV = Respiratory syncytial 
virus, Myc = Mycoplasma pneumoniae, hMpV = human metapneumovirus, PiV 
= parainfluenza virus, Flu = Influenza virus, CoV = Coronavirus, Cpp = 
Chlamydophila pneumonia) 
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Figure 3.2: Percentage of clinical diagnoses for hRV mono-infections and hRV 
co-infections (URTI = upper respiratory tract infection. Episodic Wheeze = 
episodic viral wheeze / asthma. All differences not significant p > 0.05) 
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 Co-infection was a common occurrence in the hRV population with 
more than one pathogen being detected in 70 (59%) of samples. The most 
common pathogens co-detected were AdV (n=31, 44%), hBoV (n=28, 40%) 
and RSV (n=15, 21%), with other pathogens being detected in smaller 
frequencies (Figure 3.1). Children with hRV detected were significantly more 
likely to have co-infection compared to non-hRV ARI (59% vs. 39% x2=16.1 
p<0.001), this finding remained significant if PCR negative results were 
removed from the analysis (x2=6.51 p=0.01). There were no significant 
differences in clinical diagnoses of those with hRV co-infection compared to 
mono-infection (Figure 3.2). There were no difference in rates of hospital 
admission in those with mono-infection and co-infection (54% vs. 59% 
x2=0.225 p=0.64). 
 
3.3.2  hRV Serotype analysis 
 
 All samples had the 5’ NCR region amplified and analysed to determine 
hRV strain and group. Of the 118 samples tested 104 were successfully 
analysed and characterised. Analysis was unsuccessful in the remaining 14 
samples for presumed reasons of human genomic DNA contamination, 
simultaneous detection of multiple hRV serotype infections, identification of a 
new strain that required further analysis or failure of amplification (Figure 3.3). 
The successfully amplified samples were shown to contain 49 separate strains. 
Seventy strains were from the hRV-A group and 29 from the novel hRV-C 
group (Figure 3.4 and Figure 3.5). Poliovirus or coxsackievirus were found in 
5 samples rather than hRV. No hRV-B was detected in and samples. There 
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was no significant difference in clinical or demographic data between those 
infected with hRV-A or hRV-C (Table 3.2).  Co-infection was similarly prevalent 
in both hRV groups. 
 
3.3.3 Clinical presentations 
 
 In both hRV groups the majority of ARI presentations were lower 
respiratory clinical manifestations with 84% of hRV-A group and 76% of the 
hRV-C group having ARI of the lower airway. The most common diagnosis 
was bronchiolitis in both groups, with 56% of hRV-A and 66% of hRV-C being 
discharged with this diagnosis. Pneumonia was the second most common 
diagnosis in the hRV-A group with 27% of this cohort having pneumonia. In 
contrast, EVW/asthma was the second most common diagnosis in the hRV-C 
group with 21% of children having this diagnosis (Figure 3.6). The higher level 
of episodic viral wheeze in this group was significantly higher than hRV-A with 
this diagnosis being made in only 3% (x2=6.676 p=0.01).  Upper respiratory 
tract infection was the least common diagnosis in both hRV groups (7% hRV-
A, 3% hRV-C). 
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Figure 3.3: Reasons for sample exclusion from analysis   
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Figure 3.4: Distribution of serotypes from samples of hRV-A group (All shown 
as frequency (n)) 
 
 
Figure 3.5: Distribution of serotypes from samples of the hRV-C group (all 
shown as frequency (n)) 
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Table 3.2: Patient demographics and clinical diagnoses of those with hRV-A 
subtype hRV infection and those with hRV-C infection (URTI = upper 
respiratory tract infection. EVW = episodic viral wheeze / asthma. All presented 
as n (%). * = significant difference p < 0.05) 
 HRV-A HRV-C 
N 70 29 
MALE GENDER 38 (54%) 16 (55%) 
MEDIAN AGE 
(RANGE) 
6.5 MONTHS 
(0-47) 
6 MONTHS (0-
48) 
BIRTH WEIGHT 
<2500G 
15 (21%) 5 (17%) 
BREAST FED 61 (87%) 27 (93%) 
CO-MORBIDITIES 3 (4%) 0 (0%) 
SMOKERS AT 
HOME 
32 (46%) 8 (28%) 
HOSPITAL 
ADMISSION 
28 (40%) 9 (31%) 
CO-INFECTION 40 (57%) 15 (52%) 
CLINICAL 
DIAGNOSIS: 
  
URTI 5 (7%) 1 (3%) 
BRONCHIOLITIS 39(56%) 19 (66%) 
PNEUMONIA 19 (27%) 3 (10%) 
EVW 3 (4%)* 6 (21%)* 
OTHER 4 (6%) 0 (0%) 
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Figure 3.6: Comparison of frequency of clinical diagnoses in each hRV group. 
(All expressed as percentage (%). URTI = upper respiratory tract infection. 
EVW/asthma = episodic viral wheeze / asthma. * = significant difference p < 
0.05) 
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3.4 Discussion 
 
3.4.1 Discussion 
 
Using genetic amplification techniques we have successfully classified 
104/118 (88%) hRV samples in our paediatric population of pre-school children 
presenting with ARI in Recife. We detected hRV-A in 71% of these samples 
and hRV-C in the remaining 29%. No hRV-B was detected. Analysis of clinical 
data within the hRV cohort by group showed that hRV-C was detected more 
frequently in children with a clinical diagnosis of EVW/asthma. There were 5 
samples that were identified to not be hRV and were identified as poliovirus or 
coxsackievirus. This is understandable due to the genetic similarities between 
the viruses meaning they were identified as hRV by our probes as they were 
amplified, and we did not test for these viruses in our 18 pathogen screen to 
rule out a false positive.  
Our findings demonstrate hRV as a common respiratory pathogen. It was 
detected in 19% of children presenting to Recife with ARI making hRV the 
fourth most commonly detected pathogen in our study. This is comparable to 
other ARI epidemiology studies that report prevalence to be 12-26% 115 173 202. 
 Demographic and clinical features of ARI were similar in children with and 
without hRV. However, it is interesting to note that the majority of children with 
hRV infection presented with lower respiratory tract manifestations of infection 
(bronchiolitis or pneumonia). This further supports the re-evaluation of hRV as 
an important pathogen of the lower respiratory tract. In the past, hRV has been 
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viewed as a mild pathogen unable to enter the lower respiratory tract because 
of its presumed limited ability to replicate only at 33-25°C97.  Louie et al found 
that hRV was commonly present in children with pneumonia, bronchiolitis and 
asthma that required admission to paediatric ITU203. Our findings are similar 
and demonstrate the majority of hRV infections detected to be diagnosed with 
lower respiratory pathology and only 5% of hRV ARI being confined to 
symptoms of the upper respiratory tract. These findings should be considered 
carefully because NPA collects samples from the upper airway and so we are 
assuming hRV present in the upper airway is involved in LRTI in our patients. 
A sampling method such as broncheoalveolar lavage or endotracheal 
aspiration would be required to confirm presence in the lower airway. 
In this cohort hRV-A was the most common hRV group (71%) while hRV-C 
accounted for all remaining hRV strains that were successfully analysed 
(29%). Considering the large size of our cohort it is surprising that hRV-B was 
not detected, however this group has been reported in low levels previously (0-
3%)196 197 204. The 29% prevalence of hRV-C is directly comparable to 35% and 
36% of hRV infections in children from Spain and China respectively199 205. 
However, a number of groups have reported larger proportions of hRV 
infections to be hRV-C, in 56-68%100 206. The reasons for this discrepancy are 
unclear but lie in the presentations of children recruited to the study. Both 
Arden et al and Bizzintino et al recruited children with asthma exacerbations 
and found the prevalence of hRV-C to be higher than our results; 56% Arden 
et al, 68% Bizzintino et al100 206. 
 It has been well documented in the past that hRV infection is a significant 
cause of asthma exacerbation in the paediatric patient and it would seem 
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reasonable that the burden of novel hRV-C would be greater in this group of 
presentations. The findings of Bizzintino et al also demonstrate that hRV-C is 
associated with an increased severity of asthma exacerbation further 
suggesting that hRV-C plays an important role in asthma and viral induced 
wheeze100. In contrast, and similar to our study, hRV-C prevalence appears to 
be lower in ARI. Calvo et al analysed NPA samples from children hospitalised 
with ARI and reported 35% of hRV were hRV-C. Yu Jin et al also reported 36% 
of hRV to be hRV-C in children hospitalised with ARI199 205.  
We found that hRV infection was present in all clinical presentations of ARI. 
Interestingly bronchiolitis was the most common presentation in the subgroups 
detected (hRV-A 56% and hRV-C 66%). In the hRV-A positive group 
pneumonia was the second most common clinical presentation (27%) whereas 
EVW was in hRV-C (21%). We found that hRV-C subtype was significantly 
more likely to present as viral induced wheeze compared to hRV-A. This 
finding supports the hypothesis that hRV-C is a significant cause of asthma 
exacerbation and wheeze in the paediatric population. 
 Few studies have included all ARI presentations and analysed for hRV 
group associations with clinical diagnoses. A study by Lau et al in Hong Kong 
included children and adults admitted with ARI and found a similar occurrence, 
with wheeze being more common in the hRV-C population207. Calvo et al 
undertook a similar analysis in children with ARI in Spain and found a higher 
proportion of hRV-C positive children to have asthma/recurrent wheeze but this 
difference was not significant (hRV-C 46% vs. hRV A 39%).  
Overall we have demonstrated hRV to be an important pathogen 
involved with paediatric ARI, being detected in 19% of our population and 
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being the fourth most prevalent pathogen. Clinically hRV presented as a 
variety of clinical manifestations, with the majority being either bronchiolitis or 
pneumonia which further supports the literatures re-evaluation of hRV as an 
important pathogen in lower respiratory infection. When analysing for the novel 
group, hRV-C, we found it to be commonly detected in 29% of hRV infections. 
Demographically there were no significant differences in hRV group but 
clinically we found hRV-C to be associated more commonly with EVW/ asthma 
compared to hRV-A. This is an important finding as studies involving asthma 
exacerbations have reported higher prevalence’s of hRV-C100 206. Our findings 
appear to support the current literature and highlight the novel subtype of hRV-
C as an important pathogen in paediatric asthma and wheeze. 
 
3.4.2  Further Work:  
  
Since its relatively recent discovery in 2006 much interest has been 
generated by hRV-C. We reported our findings in paediatric ARI, 
demonstrating hRV to be frequently detected in children with LRTI and 
demonstrating hRV-C to be more frequently associated with EWV/asthma than 
hRV-A. 
Further work is needed to confirm these findings of the association of hRV-
C with asthma. Although significant, the numbers of children with the diagnosis 
of EVW/asthma in our cohort was low. To date no research has been 
conducted on this pathogen in the UK and this would provide an ideal setting 
for a large investigation to confirm our results. The lack of a control group is 
especially interesting, other studies have reported hRV to be detected in high 
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levels in asymptomatic patients174. Further work could possibly accommodate 
this also. 
Our findings in context with current literature highlight hRV-C to be 
associated with asthma pathogenesis. Recent discoveries have allowed hRV-
C to be cultured for experimentation208. It would be of great interest to analyse 
why there is an association with asthma, in cell or animal models. 
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4 An investigation into the role of Interleukin 17 
in RSV infection  
4.1 Introduction 
 
Infection with RSV commonly occurs in infancy, with the majority of 
children being infected by 2 years of age. In the developed world, 1-2% of all 
infants having sufficiently severe infection to require hospitalisation, most 
commonly with bronchiolitis137. Hospitalisation with RSV infection in infancy 
has been linked to respiratory dysfunction in later life, with the prevalence of 
wheezing being increased in children up to 13 years of age37 38.  
 T-Helper (Th) cells are important in the pathogenesis of RSV 
bronchiolitis. Originally they were classified into T-helper 1 and T-helper 2 cells 
(Th-1 and Th-2) according to their secreted cytokine profile. The response of 
Th-1 cells are characterised by expression of cytokines the Interferon gamma 
(IFN-γ) and Tissue necrosis factor alpha (TNF-α)209. In contrast Th-2 cells 
express the cytokines IL-4, IL-5, IL-9 and IL-13209. The immune response to 
respiratory viral infections normally favours a response from the Th-1 subclass 
of T-helper cells31. However in the case of RSV bronchiolitis elevated levels of 
the cytokine IL-4 have been described, suggesting a role for these cells in 
disease pathogenesis31.  
Findings that children with atopic asthma in later life have elevated 
levels of Th-2 cytokines, such as IL-13, led to the hypothesis that an imbalance 
of Th-1/Th-2 cells is involved in asthma pathogenesis and may be linked to the 
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action of RSV in infancy210. IL-13 has a pleotrophic effect with an important 
role in airway hyper-responsiveness and airway remodelling of asthma211. IL-
13 has been found in high levels during RSV infection and is a suggested 
target of bronchiolitis therapy212 213. Limited success of Th-2 targeted drugs 
further suggested cells other than Th-1/Th-2 to be involved in airway 
pathology214 215. 
In recent years a novel group of T helper cells were discovered that did 
not match the classical Th-1 or Th-2 classification. This distinct group of CD4+ 
T helper cells secreted the pro-inflammatory cytokine IL-17 and so were 
termed Th-17 cells. Th-17 cells have shown to be important in the pathology of 
many diseases including Crohn’s disease, sarcoidosis, rheumatoid arthritis and 
atherosclerosis216. Experiments involving mouse and human models have also 
shown that IL-17 plays a role in both bacterial and viral infections and provides 
an important link between the innate and adaptive immune response216. The 
first discovered cytokine, IL-17A has now shown to be one of a family of six 
which have been classified IL-17A-F217. The cytokines IL-17A and IL-17F are 
produced primarily by activated CD4+ T cells and are the most researched217 
218. The receptors for both of these IL-17 cytokines are present on the 
epithelial cells of the lung218 219. A raised response to metacholine challenge 
has also been shown to correlate with levels of IL-17 in the sputum, suggesting 
that IL-17 is involved in airway hyper-responsiveness220. However, in the case 
of RSV bronchiolitis elevated levels of the cytokine IL-4 have been described, 
suggesting a role for these cells in disease pathogenesis31. 
IL-17 has shown to be important in both neutrophil recruitment and 
acute inflammation, causing expression of the cytokines IL-8 and IL-6 from 
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airway epithelial cells221. The presence of IL-17 has also been shown to 
increase the effect of other inflammatory cytokines. Synergy has been 
demonstrated with IL-1β and TNF-α causing significant increase in pro-
inflammatory cytokines when IL-17 was present222 223. Both of these findings 
highlight IL-17 as an important cytokine in acute inflammation, a key feature of 
RSV infection of the airways in the lungs of infants. It also raises questions 
over the role of IL-17 in RSV infection. To date no study has measured the 
response of airway epithelial cells to RSV infection in the presence of IL-17.  
In this chapter, the effects of both IL-13 and IL-17(specifically IL-17A) 
and IL-13+IL-17 together have been examined on airway epithelial cells in the 
context of RSV infection. An immortalised airway epithelial cell line (BEAS-
2Bs) has been used as the model in which to assess these effects with the 
inflammatory cytokines IL-6 and IL-8 used as outcome measures.  
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4.2 Methods 
 
4.2.1  Cell Culture 
 
 To measure the response of airway epithelial cells to stimulation with 
cytokines and RSV, the immortalized airway epithelial cell line BEAS-2Bs was 
used. These cells were cultured in a T75 flask, previously coated with collagen 
buffer for 24 hours. BEAS-2Bs were grown in a solution of BEGM, with 
medium being changed three times per week and a phosphate buffered saline 
(PBS) wash being performed at each change (Details of reagents and 
manufacturers for this chapter can be seen in Appendix A.3). Once the T75 
flask of cells reached confluence, the cells were transferred into a 96-well 
culture plate at a density of 30,000 cells/cm2 and grown in BEGM until they 
were 70% confluent. 
 
4.2.2  RSV infection and cytokine stimulation 
 
Cultures were infected with 0.25 multiplicity of infection (MOI) RSV-A2 
and stimulated with IL-17A or IL-13 or IL-17 and IL13 at concentrations of 
1ng/mL, 10ng/mL and 100ng/mL. Dr Fonceca and Dr McNamara had 
previously found that an MOI of 0.25 caused significant inflammation but did 
not destroy the cultures 224.  
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 Stimulated and infected cultures were harvested at 24 and 48 hours. 
Cell supernatants were collected and stored at -70°C and RLT buffer added to 
cultured cells and also stored at -70°C until needed for analysis.  
 
4.2.3   ELISAs 
 
 Secretion of IL-6 and IL-8 from stimulated or infected airway epithelial 
cells was measured by ELISA (R&D systems) according to manufacturer’s 
instructions. Samples were diluted five times with reagent diluent in non-RSV 
infected supernatants and ten times in RSV infected supernatants. Results 
were calculated by use of a standard curve as described by manufacturer. The 
ELISAs were sensitive to a concentration of 30pg/mL. 
 
4.2.4  Statistics 
 
 Statistical analysis was performed using the statistics package SPSS 
(version 18.0.0). Results are presented as average +/- standard deviation or 1 
standard error (2 standard errors in graphs). In the case of normally distributed 
data the student-t test was used to compare variation between samples, with 
ANOVA utilised to analyse variation across groups. Results were considered 
significant if p ≤0.05. For ELISA data results were presented as value ± 
standard error of mean (± 2 in graphs), with results shown to 3 significant 
figures. 
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4.3 Results 
 
4.3.1 – IL-6 responses in BEAS-2B cells infected with RSV and stimulated 
with IL-17 and IL-13 
 
 Secreted IL-6 from airway epithelial cells stimulated by IL-17, IL-13 and 
IL-17+IL-13 in the presence and absence of RSV infection was measured by 
ELISA.  
At 24 hours, IL-6 concentrations were significantly raised in RSV-
infected compared to non-infected culture without addition of cytokine 
supernatants (RSV-infected control: 13,800±6620 pg/ml control: 700±92 pg/ml 
p=0.02). However, there were no other significant differences between control 
cultures and RSV infected without cytokine present and/or cytokine stimulated 
cultures (Figure 4.1 A, and Figure 4.1B). 
 At 48 hours IL-6 responses to IL-17 and IL-17+IL-13 stimulation in the 
presence of RSV infection were significantly greater than those in un-infected 
cultures where RSV was not present (Figure 4.2 A and Figure 4.2 B). In RSV 
infected cultures IL-6 secretion was significantly greater with addition of 
cytokine than RSV infected cultures without cytokine when stimulated with 
10ng/ml IL-17 (109,000±29300pg/mL vs. 25,900±4880 pg/mL p=0.049) and 
100ng/mL IL-17 (120,000±19500 pg/mL vs. 25,900±4880 pg/mL 
p=0.009).Although mean IL-6 production was increased in response to IL-13, 
no significant differences were observed for any concentration of IL-13 
compared to the RSV-infected control. 
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Figure 4.1 A: IL-6 production (pg/mL) by BEAS-2B cells stimulated with IL-17 
and/or IL-13 in the presence or absence of RSV infection at 24 hours.  
(* = p<0.05 compared to control in RSV negative / RSV control in RSV positive 
samples) 
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Figure 4.1B:  IL-6 production (pg/mL) by BEAS-2B cells stimulated with IL-17 
and/or IL-13 in the absence of RSV infection at 24 hours.  
(* = p<0.05 compared to control in RSV negative / RSV control in RSV positive 
samples) 
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Figure 4.2 A: IL-6 production (pg/mL) by BEAS-2B cells stimulated with IL-17 
and/or IL-13 in the presence or absence of RSV infection at 48 hours.  
(* = p<0.05 compared to control in RSV negative / RSV control in RSV positive 
samples) 
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Figure 4.2 B: IL-6 production (pg/mL) by BEAS-2B cells stimulated with IL-17 
and/or IL-13 in the absence of RSV infection at 48 hours. 
 (* = p<0.05 compared to control in RSV negative / RSV control in RSV 
positive samples) 
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IL-6 production was increased when stimulated simultaneously with IL-
17 and IL-13 in the presence of RSV compared to RSV control at 
concentrations (both cytokines) of 1ng/mL (73,000±13,600 pg/mL vs. 
25,900±4,880 pg/mL p=0.031) and 10ng/mL (105,000±14,700 pg/mL vs. 
25,900±4,880 pg/mL p= 0.007) with a trend observed at a concentration of 
100ng/mL (10,300±48,100 pg/mL vs. 25,900±4,880 pg/mL p=0.053).  
 
4.3.2  – IL-8 responses in BEAS-2B cells infected with RSV and stimulated 
with IL-17 and IL-13  
 
 Secreted IL-8 by BEAS-2B cells was measured in a similar manner to 
IL-6. 
 At 24 hours significant increases in IL-8 expression were observed in 
the presence of IL-17 and RSV infection (Figure 4.3). IL-8 production was 
greater when stimulated with IL-17 at a concentration of 1ng/ml (799±21 pg/mL 
vs. 571±75 pg/mL p=0.042) and 100 ng/mL (916±65 pg/mL vs. 571±75 pg/mL 
p=0.025). The mean IL-8 expression at 10 mg/ml was higher than RSV control 
but this was not significant. There was no significant response to stimulation 
with IL-13. In the presence of IL-17 and IL-13 at 1ng/ml significant expression 
was observed (861±63 pg/mL vs. 571±75 pg/mL p=0.04). 
 At 48 hours no significant increase in IL-8 expression was observed with 
any combination of cytokines (Figure 4.4). Similarly to 24 hours there was no 
observable increase in IL-8 expression comparing RSV infected control to RSV 
non-infected control (429±78 pg/mL vs. 658±60 pg/mL p=0.13). 
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Figure 4.3: IL-8 production (pg/mL) by BEAS-2B cells stimulated with IL-17 
and/or IL-13 in the presence or absence of RSV infection at 24 hours.  
(* = p<0.05 compared to control in RSV negative / RSV control in RSV positive 
samples) 
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Figure 4.4: IL-8 production (pg/ml) by BEAS-2B cells stimulated with IL-17 
and/or IL-13 in the presence or absence of RSV infection at 48 hours. 
(* = p<0.05 compared to control in RSV negative / RSV control in RSV positive 
samples) 
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4.4 Discussion 
 
In the presence of RSV infection, IL-17 caused significantly increased 
expression of the pro-inflammatory cytokines IL-6 at 48 hours and IL-8 at 24 
hours. There was no significant change in secretion of these cytokines by 
BEAS-2B cells with IL-17 in the absence of RSV infection. The cytokine IL-13 
demonstrated no effect on the expression of either of these cytokines in the 
presence or absence of RSV. These findings suggest that IL-17 and IL-13 do 
not act in a synergistic way to induce expression of IL-6 and IL-8 in an airway 
epithelial cell model.  
 
4.4.1 – IL-6 expression of BEAS-2Bs in response to stimulation 
 
  In the absence of RSV infection, IL-6 production by BEAS-2B cells was 
not significantly altered upon addition of varying concentrations of IL-17. This 
result is in contrast to that reported by Jones et al who found that IL-17 caused 
significantly increased expression of IL-6 by primary human bronchial epithelial 
cells221. Jones et al used primary airway epithelium from human samples 
whereas we used the immortalised cell line BEAS-2Bs. It may be the case that 
primary cells demonstrate a greater response to IL-17 stimulation221. However 
Van den Berg et al reported that IL-17 produced no significant increase in IL-6 
expression in the absence of other cytokines223. This study was also 
completed in primary airway epithelial cells and only upon addition of TNFα 
and IL-17 was a response induced 223. Our results agree with Van den Berg et 
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al showing IL-17 in isolation has no significant effect on IL-6 expression in the 
bronchial epithelium.   
 On addition of RSV-A2 we found a large increase in epithelial cell 
expression of IL-6. This finding is in keeping with the literature as IL-6 is a well 
recognised early cytokine in RSV infection and has been found to be elevated 
in the airways of infants with bronchiolitis, with airway epithelial cells a proven 
source225 226. At 24 hours there were no significant differences in the groups 
treated with differing cytokine concentrations. There was a possible trend to IL-
17 inducing higher levels of IL-6 compared to RSV control, especially at a 
concentration of 100ng/mL, but this result was not significant. However, at 48 
hours significant increases in IL-6 production were seen with IL-17 present at 
concentrations of 10ng/mL and 100ng/mL, compared to RSV infected control. 
No group has yet reported the effect of IL-17 on airway epithelium cells in the 
context of RSV infection. Wiehler et al demonstrated that hRV-16 infection 
caused significantly elevated expression of inflammatory cytokines if IL-17 was 
present, including IL-6 expression227. Weihler et al went on to suggest that IL-
17 had an effect at the post-transcriptional level and may have implications on 
other inflammatory cytokines and immune cell recruitment227. Similarly our 
results suggest in the presence of IL-17 and RSV the cytokine milieu is 
conducive to increased IL-6 expression from airway epithelial cells. Our 
findings appear to be similar to Weihler et al’s but are the first reported 
description of this in RSV infection of epithelial cells. Jones et al reported the 
effect of IL-17 on primary airway epithelial cells and also demonstrated that IL-
6 production was increased of 48 hours compared to 24 hours221. With similar 
methodology Jones et al stimulated primary human bronchial epithelial cells 
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with IL-17 and found significant increase of IL-6 at 24 hours and even greater 
at 48 hours221. Previous studies have demonstrated IL-17 to have an effect on 
mRNA at the post-transcriptional level, increasing the concentration of mRNA 
in epithelial cells when responding to the cytokines TNFα and IL-1β222 223. 
Together these reported findings support the findings of significant increases 
of IL-6 being seen at 48 hours rather than 24.  
A role for IL-6 has been demonstrated in the induction of IL-17 and 
differentiation of naive T cells to the Th-17 subtype228. In an environment with 
IL-6 present it has been shown naive Th cells differentiate into active Th-17 
cells by a STAT3 mediated mechanism229. This suggests IL-17 present during 
RSV infection might further induce IL-6 from the airway epithelium and thereby 
a possible source of IL-6 causing TH-17 differentiation. If this were to cause a 
positive feedback response, raised IL-17 would be likely to cause rapid 
neutrophil recruitment and airway neutrophilia, similar to that witnessed in over 
50% of asthma exacerbations213.  
Our results show IL-6 was not raised when airway epithelial cells were 
stimulated with IL-13, suggesting IL-13 may have a minor role in acute 
inflammation of the airway epithelium. Previous literature has described IL-13 
to be involved in eosinophilia of the airway, a feature associated with chronic 
asthma as opposed to severe asthma exacerbations212 230. Our results suggest 
IL-13 may be effect a cell type other than airway epithelial cells. IL-13 causing 
IL-6 expression in airway epithelial cells has not been described previously. 
Given that IL-13 in isolation produced no significant effect on IL-6 
expression it was perhaps not surprising that a synergistic effect of IL-13 and 
IL-17 on epithelial cell IL-6 secretion was not observed. IL-6 production by 
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samples stimulated with IL-17 and IL-13 was significantly increased in the 
presence of RSV infection at 48 hours. However at these concentrations IL-17 
in isolation caused significant increase in IL-6 expression and so it is unlikely 
IL-13 was causative of this increase. Previous studies which have 
demonstrated synergy with the cytokines TNF-α and IL-1β, have both shown 
the respective cytokines to cause expression of IL-6 prior to addition of IL-17222 
223.  
 
4.4.2 – IL-8 Expression of BEAS-2Bs in response to cytokine stimulation 
  
 We found that in the absence of RSV infection there was no significant 
change in IL-8 protein production in BEAS-2B cells exposed to IL-17. Previous 
reports have also shown no significant increase in IL-8 production when 
exposed to IL-17 in isolation221. In addition, studies by Dragon et al and Van 
den Berg et al found that IL-17 in isolation did not induce a significant change 
in IL-8 production in primary airway cells when treated with similar 
concentrations of IL-17222 223. Earlier studies demonstrated IL-17 as a potent 
inducer of IL-8 in peripheral blood mononuclear cells (PBMC) which express 
an IL-17 RA and IL-17RC receptor217 231. Despite the presence of these 
receptors in airway epithelial cells our results suggest that IL-17 does not 
cause expression of IL-8 in BEAS-2B cells.  
 Upon addition of RSV infection to our samples significant increases in 
IL-8 protein production were observed. There was no significant increase in IL-
8 expression upon addition of RSV. Oh et al has previously demonstrated IL-8 
to not be significantly elevated in NPA samples of children with RSV 
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infection225. However Larranaga et al found the converse with IL-8 significantly 
raised in the NPAs of RSV bronchiolitis children232. Other airway cell types 
have been previously shown to produce IL-8 in RSV infection, such as alveolar 
macrophages233. The reason for this may be that NPA samples collect 
secretions of expressed cytokines from many different cell types, not just 
airway epithelial cells. 
We found elevated expression of IL-8 in RSV infected BEAS-2Bs when 
IL-17 was present at 24 hours. Our study is the first to measure the combined 
effects of IL-17 and RSV infection in an airway epithelial model. IL-8 is a potent 
neutrophil recruiter and high levels of neutrophils are found in the paediatric 
airway in both RSV bronchiolitis and acute asthma exacerbations213 234. The 
finding of elevated IL-8 expression at 24 hours and not 48 hours suggests that 
IL-17 may play a role in increasing IL-8 expression in the acute phase of 
infection.  
 These results also demonstrate IL-13 does not induce significant IL-8 
expression in airway epithelial cells. This is the first study to examine the effect 
of IL-13 on expression of IL-8 from airway epithelial cells. This could represent 
that IL-13 affects a different cell type in the airway, with no IL-13 receptor 
having been described in airway epithelial cells.  
There was no demonstrable synergy when BEAS-2Bs were stimulated 
with IL-17 and IL-13 simultaneously, infected or not infected with RSV.  
 
4.4.3 – Further Work 
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 This chapter has characterised the cytokine response to IL-17 and IL-13 
in the presence and absence of RSV infection. This work has raised a number 
of areas for further study however. 
 There appears to be some debate in the literature about primary airway 
epithelial cells response to IL-17 with different results being reported221 223. If 
these experiments were to repeat in primary cell cultures based on airway 
epithelial cells obtained from bronchial brushing it would be the first reported 
study involving RSV infection and IL-17 and would also add to the evidence 
base on IL-17s role in inflammation in the lung. It would also be possible to 
examine whether these responses differ in epithelial cells in individuals with 
other conditions such as asthma or cystic fibrosis. 
 Our finding of IL-13 causing no expression of either cytokine is 
important as no other study has reported this finding previously. A suggested 
reason for this was that no study had characterised an IL-13 receptor on 
airway epithelial cells and so it may be a further project to analyse airway 
epithelial cells for the presence of an IL-13 receptor.  
  
4.4.4 – Conclusions 
 
 Taken together our results have highlighted IL-17 as an important 
cytokine in the processes of airway inflammation and neutrophil recruitment 
during RSV infection. We have shown that in isolation IL-17 appears to have 
no significant affect of the cytokines we analysed, only once a second 
stimulation occurs does IL-17 appear to augment the effect. We also found 
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that IL-13 has no apparent effect on airway epithelial cells to express these 
cytokines which is important as IL-13 is found in elevated levels in the airways 
of asthmatics and is a publicised target for treatment of RSV-disease212. 
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5 Final discussion and further work 
 
5.1 Overview 
 
Paediatric ARI represents the largest identifiable cause of mortality in 
children under five years worldwide153. This highlights ARI as an important 
area for research and has been chosen as a primary target of the Millennium 
Development Goal to reduce childhood mortality139. We aimed to assess the 
prevalence of causative pathogens of ARI as well as characterising the clinical 
and demographic features of novel respiratory pathogens H1N1 and hRV-C. 
Finally we aimed to investigate the interaction between IL-17 and IL-13, and 
RSV infection in airway epithelial cells. By adding to the literature it will enable 
further work into the causative pathogens of ARI and the immune response 
that leads to pathology in respiratory infection. This thesis has succeeded in 
each of these aims and highlighted further areas for research. The overall 
findings of each chapter are as follows: 
 
5.1.1 Aim 1 – To characterise the viral and atypical bacterial pathogens 
detected in children <5 years presenting to hospital in Recife, Brazil 
with ARI. The secondary aim was to characterise the clinical and 
demographic features of children in whom H1N1 was detected 
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 Full assessment of the causative pathogens of ARI is important in 
targeting treatments in ARI. Previously much research has been undertaken 
on bacterial pathogens as they responded well to traditional culturing 
techniques, with vaccines being developed for the two most common - Hib and 
pneumococcus. Comparatively less is known about viral pathogens of ARI. 
The development of PCR as a diagnostic technique has allowed high 
throughput rapid viral diagnostics in virology centres. New respiratory viruses 
have been identified in recent years as well as documented viruses 
undergoing mutations and altering their clinical importance. The most recent 
influenza virus to mutate, H1N1, spread rapidly reaching the level of global 
pandemic and paediatric patients were at high risk of severe disease126.We 
collected NPAs from children presenting with ARI to IMIP children’s hospital, 
Recife, Brazil between March 2008 and April 2010. In this setting viral 
diagnostics are not usually available, but samples were transported to 
Liverpool, UK where multiplex PCR was undertaken for 18 different viral and 
atypical bacterial pathogens.  
We were successful in analysing for the chosen pathogens and 
demonstrated high detection rates in 88% of the 630 samples. The most 
common pathogens detected were RSV, AdV, hBoV and hRV (33%, 29%, 
25% and 19% respectively). Levels of AdV and hBoV were higher than other 
reports in the literature and explanations may be the young age of our cohort 
or the crowded living conditions in which they live102 169. We also reported high 
levels of co-infection with 43% of children having more than one pathogen 
detected on PCR. This was higher in other literature and may reflect the wide 
variety of pathogens we tested for or the living conditions of the children we 
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recruited. The most common pathogens detected as co-infections were AdV, 
hBoV and RSV (54%, 48% and 37%). Our findings highlight the wide variety of 
pathogens that are detected in children presenting with ARI.  
 Our secondary aim was to characterise the clinical and demographic 
features of novel H1N1 influenza. The timing of our study allowed us to 
characterise the emergence H1N1 and compare the pre-pandemic year 
(March 2008-March 2009) to the pandemic year (April 2009- March 2010). We 
were able to show influenza to be the pathogen with greatest change in 
prevalence, quintupling from 3% to 15%. H1N1 represented 79% of the flu 
cases in the pandemic year. Demographically there were no significant 
differences in those with H1N1 ARI compared to non-H1N1 flu, or non-flu ARI. 
However those diagnosed with H1N1 were more likely to require 
hospitalisation for ARI and have more than one pathogen detected on PCR. 
Overall H1N1 represented a significant pathogen in the pandemic year and 
during its peak was detected in 30% of ARI samples in a month and all cases 
of H1N1 presenting as a LRTI. We hypothesised that based on previous 
literature there would be demonstrable differences in H1N1 ARI and we 
confirmed higher hospitalisation rates in the H1N1 cohort.  
 Our findings also raised questions to the role of co-infection in our 
cohort. Co-infections have been reported in the literature previously and their 
importance questioned, most recently in relation to H1N1 infection186.  Our 
findings highlight the need for further assessment of co-infection in paediatric 
ARI. 
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5.1.2  Aim 2 – To describe the role of novel hRV group, hRV-C, in 
paediatric ARI 
 
 hRV represents a common respiratory virus detected in childhood ARI, 
we found it to be present in 19% of children with ARI. In the past hRV was 
regarded as a trivial respiratory infection and limited to the upper airway. 
However it has since been proven hRV is an important cause of LRTIs as well 
as playing a role in asthma exacerbations97. Recent diagnostic methods have 
also shown that the previous classification of hRV into two groups was 
incomplete with novel hRV-C being discovered. Novel hRV-C has shown to be 
present in severe asthma exacerbations although its role in ARI in unknown100. 
We aimed to characterise the clinical and demographic features of hRV 
infection and compare novel hRV-C infection to other groups.  
We succeeded in characterising the clinical and demographic features 
of hRV positive ARI. Compared to non-hRV ARI we found no demographic or 
clinical differences, however levels of co-infection were increased. hRV rarely 
presented as an URTI (5%) with the most common diagnoses being 
bronchiolitis (58%) and pneumonia (25%), this was in keeping with our 
hypothesis that hRV would be present in LRTI presentations. 
 Further analysis was successfully achieved in majority of samples with 
99 (84%) assigned a hRV strain. hRV-A was the most common group (71%) 
with all other samples being hRV-C (29%), no hRV-B was detected. 
Demographically there was no significant difference in patients presenting with 
hRV-A or hRV-C infection. hRV-C more commonly presented with the 
diagnosis of EVW / asthma (p=0.01). This also correlated with our original 
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hypothesis and the previous literature on the topic, that hRV-C has a role in 
EVW/asthma presentations. We found no significant difference in disease 
severity in the hRV-C group with regards hospitalisation or other clinical 
demographics. 
Our results also highlighted that the literature was lacking in determining 
prevalence of hRV-C in children without symptoms of ARI. It has been 
previously shown in studies into ARI epidemiology that  hRV is commonly 
detected in asymptomatic patients174. However no study has yet performed this 
analysis and accounted for separate hRV groups. Future topics should aim to 
further our understanding of hRV-C in respiratory disease and reason for why it 
induces EVW/asthma presentations, this could involve looking at the induced 
cytokines associated with specific strains of hRV.   
 
5.1.3 Aim 3 – To determine the role of IL-17 in RSV infection of airway 
epithelial cells and measure for synergy with IL-13.  
 
 IL-17 is a pro-inflammatory cytokine that has been highlighted as being 
detected in the airways of asthmatic children235. RSV is one of the most 
common respiratory pathogens to infect infants and is associated with asthma 
and wheeze in later life37 38. IL-17 has shown a synergistic response when 
combined with the pro-inflammatory cytokines TNF-α and IL-1β222 223. We 
aimed to determine the role of IL-17 in RSV infection of airway epithelial cells 
and measure for synergy with the Th-2 cytokine IL-13. 
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 By utilisation of ELISA techniques we were able to successfully show 
that in the presence of IL-17 significantly increased expression of the pro 
inflammatory cytokines IL-6 at 48 hours and IL-8 at 24 hours was observed. IL-
6 is an important cytokine involved in inflammation and IL-8 is involved in 
neutrophil recruitment to the airway.  Our results add to the literature on IL-17 
in airway disease which highlights IL-17 to not cause significant inflammatory 
response in isolation, however when exposed to RSV infection in the presence 
of IL-17 significant expression of IL-6 and IL-8 are observed in the airway 
epithelial models. We also characterised IL-13 to cause no expression of these 
cytokines from airway epithelial cells which is of interest as IL-13 has been 
studied as an important cytokine in RSV disease and a target for RSV 
treatment212. 
 Overall we have highlighted IL-17 as an important cytokine in RSV 
disease and to act upon airway epithelial cells to cause expression of pro-
inflammatory cytokines. Further work is necessary to describe the role of IL-17 
in asthma exacerbation and also determine the reason for the ability of IL-17 to 
augment immune responses in respiratory infection and inflammation. 
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6 Appendix 
 
6.1 A.1: RT-PCR primers 
The following primer sets were used for pathogen detection by RT-PCR. 
All primer probes were supplied by Dr M Hopkins. Work has been previously 
published on these probes and coding from oligonucleotide probes is extracted 
directly from references167 177: 
From Bezerra et al167: (References in table – 32236  27237  33238) 
“Table 1. Additional oligonucleotide primers and probes used in this study.  
“167
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From Hopkins et al177: (References in table – 176237 239  184   19240   7236  20241) 
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6.2 A.2: Cycling conditions for pathogen detection PCR 
 
 Temperature (°C) Duration Number of Cycles 
Flu, H1N1, hMPV, RSV, 
CoV, PIV, hRV 
50 20 minutes 1 
95 2 minutes 1 
95 10 seconds 50 
58 45 seconds 
72 1 second 
40 30 seconds 1 
AdV, Mpp, Cpp 95 5 minutes 1 
95 10 seconds 50 
95 10 seconds 
58 45 seconds 
72 1 second 
hBoV 95 15 minutes 1 
 95 10 seconds 50 
 58 45 seconds  
 72 1 second  
 
6.3 A.3: Reagents and manufacturers 
 
 More detailed information on reagents and manufacturers utilised in the 
methodology of chapter 4 is as follows: 
 Bronchial epithelial growth medium (BEGM) was made from 500mL 
volume of BEBM (Lonza Walkerville Inc) to which the following were 
added: Bovine pituitary extract, hydrocortisone, epidermal growth factor, 
epinephrine, insulin, transferrin, tri-iodothyronine, retinoic acid and 
gentamicin. 
 Phosphate buffered saline was purchased from Sigma, St Louis, USA. 
 The cytokines IL-17 and IL-13 used for stimulation were obtained from 
R&D systems, Oxford, UK 
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 RSV-A2 virus was obtained from Dr Angela Fonceca 
 Reagents used for reverse transcription in this chapter were all 
purchased from Promega, UK. 
 Buffer RLT was purchased from Qiagen, Crawley, UK as was total RNA 
extraction kit 
 Duoset ELISA kits were purchased from R&D systems, Oxford, UK 
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